Vaccinogen (VGEN) Inactive 10-Q14 May 142014 Q1 Quarterly reportFinancial data

Company Profile

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
Document And Entity Information	Mar. 31, 2014	13-May-14
Document Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Mar-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'
Trading Symbol	'VGEN	'
Entity Common Stock, Shares Outstanding	'	32,043,753
Entity Registrant Name	'VACCINOGEN INC	'
Entity Central Index Key	'0001453001	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Mar. 31, 2014	Dec. 31, 2013
Assets	'	'
Cash and cash equivalents	$62,567	$73,096
Restricted cash	44,473	44,394
Inventory	99,250	100,150
Prepaid expenses and other current assets	235,338	115,522
Total Current Assets	441,628	333,162
Prepaid expenses and other assets	0	0
Property and equipment, net	189,953	198,790
Intangible assets, net	61,049,742	62,725,559
Total Assets	61,681,323	63,257,511
Liabilities and Stockholders' Equity	'	'
Financial instruments	10,169,317	11,794,790
Notes payable	4,403,803	4,831,217
Accounts payable	2,759,213	3,357,287
Accrued compensation	1,191,578	1,108,541
Accrued interest	901,347	863,637
Accrued expenses and other liabilities	761,926	639,448
Related party payable	0	54,099
Total Current Liabilities	20,187,184	22,649,019
Total Liabilities	20,187,184	22,649,019
Commitments and Contigencies	'	'
Stockholders' Equity	'	'
Preferred stock, $0.0001 par value: 50,000,000 shares authorized; 0 shares issued and outstanding	0	0
Common stock, $0.0001 par value; 200,000,000 shares authorized; 32,015,480 and 31,568,629 shares issued and outstanding at March 31, 2014 and December 31, 2013, respectively.	3,202	3,157
Additional paid-in capital	146,484,487	143,920,855
Accumulated other comprehensive loss	-36,112	-36,199
Accumulated deficit	-104,957,438	-103,279,321
Total Stockholders' Equity	41,494,139	40,608,492
Total Liabilities and Stockholders' Equity	$61,681,323	$63,257,511

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred Stock, Shares Authorized	50,000,000	50,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common stock, par value (in dollars per share)	$0.00	$0.00
Common Stock, Shares Authorized	200,000,000	200,000,000
Common Stock, Shares, Issued	32,015,480	31,568,629
Common Stock, Shares, Outstanding	32,015,480	31,568,629

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (USD $)	3 Months Ended
Condensed Consolidated Statements of Operations (USD $)	Mar. 31, 2014	Mar. 31, 2013
Revenues	$0	$0
Operating Expenses:	'	'
Research and Development	2,020,128	2,073,184
General and administrative expenses	707,927	6,929,760
Total Operating Expenses	2,728,055	9,002,944
Loss From Operations	-2,728,055	-9,002,944
Gain (Loss) on Financial Instruments	1,902,823	-413,895
Interest Expense and Other Expenses	-852,885	-65,230
Net Loss	-1,678,117	-9,482,069
Net loss available to common stockholders	($1,678,117)	($9,482,069)
Basic and diluted weighted average shares outstanding	31,657,798	19,794,127
Basic and diluted loss per common share	($0.05)	($0.48)

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Comprehensive Loss (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Comprehensive Loss	'	'
Net loss	($1,678,117)	($9,482,069)
Foreign currency translation adjustments	87	35,463
Total Comprehensive Loss	($1,678,030)	($9,446,606)

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Changes in Stockholders' Equity (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Beginning Balance at Dec. 31, 2013	$40,608,492	$3,157	$143,920,855	($103,279,321)	($36,199)
Beginning Balance (in shares) at Dec. 31, 2013	'	31,568,629	'	'	'
Issuance of common stock for cash	1,500,605	39	1,500,566	0	0
Issuance of common stock for cash (in shares)	'	386,103	'	'	'
Conversion of 2012 Bridge Loan for common stock	227,939	6	227,933	0	0
Conversion of 2012 Bridge Loan for common stock (in shares)	'	56,075	'	'	'
Conversion of payable to common stock	18,967	0	18,967	0	0
Conversion of payable to common stock (in shares)	'	4,673	'	'	'
Contingent Warrants	793,563	0	793,563	0	0
Stock-based compensation	22,603	0	22,603	0	0
Other comprehensive income	87	0	0	0	87
Net Loss	-1,678,117	0	0	-1,678,117	0
Ending Balance at Mar. 31, 2014	$41,494,139	$3,202	$146,484,487	($104,957,438)	($36,112)
Ending Balance (in shares) at Mar. 31, 2014	'	32,015,480	'	'	'

Condensed_Consolidated_Stateme3

Condensed Consolidated Statements of Cash Flows (USD $)	3 Months Ended
Condensed Consolidated Statements of Cash Flows (USD $)	Mar. 31, 2014	Mar. 31, 2013
Cash Flows From Operating Activities	'	'
Net loss	($1,678,117)	($9,482,069)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation	9,504	7,356
Amortization of intangible assets	1,675,816	1,675,817
(Gain) Loss on financial instruments	-1,902,823	413,895
Other Stock based expense	0	5,954,545
Stock based compensation - employees	22,603	0
Non-cash interest expense	793,563	0
Changes in operating assets and liabilities, net:	'	'
Accrued interest	37,711	25,888
Changes in restricted cash	-79	-165
Prepaid expenses and other assets	106,459	-28,294
Accounts payable and accrued expenses and other liabilities	-606,038	431,490
Net Cash Used In Operating Activities	-1,541,401	-1,001,537
Cash Flows From Investing Activities	'	'
Purchases of property and equipment	0	-722
Net Cash Used In Investing Activities	0	-722
Cash Flows From Financing Activities	'	'
Repayments of Abell Loan	-427,415	0
Repayments of related party notes payable	-54,099	0
Proceeds from issuance of common stock and warrants	999,866	971,836
Net Cash Provided by Financing Activities	1,518,352	971,836
Impact of foreign currency translation on cash and cash equivalents	12,520	40,752
Net (Decrease) Increase in Cash and Cash Equivalents	-10,529	10,329
Cash and Cash Equivalents, beginning of period	73,096	113,840
Cash and Cash Equivalents, end of period	$62,567	$124,169

Organization

Organization	3 Months Ended
	Mar. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Nature of Operations [Text Block]	'
	1	Organization

	The Business

	Vaccinogen, Inc. (the “Company” or “Vaccinogen”), a biotechnology Company headquartered in Frederick, Maryland, was incorporated in the State of Delaware during 2007 for the purpose of developing therapies and vaccines to combat cancer by using the body’s own immune system. On November 23, 2010, the Company changed its domicile from Delaware to Maryland by means of a merger of the Company with and into its wholly owned subsidiary Vaccinogen I, Inc., a Maryland corporation.

	On October 10, 2007, the Company entered into a license agreement with Intracel Holdings Corporation (“Intracel”), a related party, for the exclusive and indefinite rights to use the OncoVAX® technology platform. OncoVAX® is an active specific immunotherapy (“ASI”) that uses the patient’s own cancer cells to create a vaccine that in turn is used to block the return of cancer following surgery. In June 2010, the Company entered into an agreement with Intracel (the “Asset Transfer Agreement”) whereby the Company acquired title to the patents associated with the OncoVAX® (See Note 4). On October 23, 2007, Vaccinogen acquired out of bankruptcy, certain tangible assets that had been previously owned and used by Intracel’s wholly owned subsidiary in the Netherlands. These assets will be used to conduct research and development and in the commercialization of OncoVAX® to produce vaccines. In connection with the acquisition of these assets, the Company formed a wholly owned subsidiary, Vaccinogen BV, for the purposes of continuing development of OncoVAX®.

Going_Concern

Going Concern	3 Months Ended
	Mar. 31, 2014
Going Concern [Abstract]	'
Going Concern [Text Block]	'
	2	Going Concern

	The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has recurring losses and as of March 31, 2014, the Company had an accumulated deficit of approximately $104.9 million and negative working capital of approximately $19.7 million. Since inception, the Company has financed its activities principally from the proceeds from the issuance of equity and debt securities and loans from officers.

	The Company’s ability to continue as a going concern is dependent upon the Company’s ability to raise additional debt and equity capital. There can be no assurance that such capital will be available in sufficient amounts or on terms acceptable to the Company. These factors raise substantial doubt about the Company's ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability of the recorded assets or the classification of liabilities that may be necessary should the Company be unable to continue as a going concern.

	We do not have sufficient capital to fund our plan of operations over the next twelve months. In order to address our capital needs, including our planned Phase IIIb clinical trial, we are continuing our private offering of Units, and we are actively pursuing additional equity or debt financing, in the form of either a private placement or a public offering. We have been in ongoing discussions with strategic institutional investors and investment banks with respect to such possible offerings. We have identified a potential investor as outlined in Note 15 to these unaudited condensed consolidated financial statements. Such additional financing opportunities might not be available to us, when and if needed, on acceptable terms or at all. If we are unable to obtain additional financing in sufficient amounts or on acceptable terms under such circumstances, our operating results and prospects will be adversely affected.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	3. Summary of Significant Accounting Policies

	Basis of Presentation

	The accompanying unaudited condensed consolidated financial statements as of March 31, 2014 and for the three months ended March 31, 2014 and 2013, respectively include the accounts of Vaccinogen, Inc. and its wholly owned subsidiary and have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) and, therefore, omit or condense certain disclosures and other information required under generally accepted accounting principles in the United States of America (“US GAAP”) for complete financial statements. These unaudited condensed consolidated financial statements should therefore be read in conjunction with the audited consolidated financial statements and the accompanying notes for the year ended December 31, 2013.

	In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all the adjustments and reclassifications necessary for a fair presentation for the periods presented in accordance with US GAAP. The results for the three months ended March 31, 2014 are not necessarily indicative of the results to be expected for the full year.

	Principles of Consolidation

	The unaudited condensed consolidated financial statements include accounts of Vaccinogen and its wholly owned subsidiary, Vaccinogen BV (a company incorporated in the Netherlands). All intercompany balances and transactions have been eliminated in consolidation.

	Use of Estimates

	The preparation of unaudited condensed consolidated financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in its financial statements. On an ongoing basis, the Company evaluates the estimates used in recording common stock warrant related liabilities, derivative financial instruments, stock based compensation, and where applicable, the fair value of assets. The Company may base such estimates on various assumptions which it believes to be reasonable under the circumstances. Actual results could differ from those estimates.

	Cash and Cash Equivalents

	The Company considers all highly liquid securities with a maturity of three months or less at acquisition to be cash equivalents. Cash and cash equivalents include demand deposits with financial institutions and at times the amounts may exceed federally insured deposit limits. The Company has not experienced any losses and does not believe it is exposed to any significant credit risk related to demand deposits.

	Restricted Cash

	Restricted cash represents monies pledged by the Company’s foreign subsidiary for a lease obligation related to the manufacturing facility and to the Dutch government as required for companies with irradiator equipment.

	Concentrations of Credit Risk

	Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains its cash and cash equivalents with high-credit-quality financial institutions in the United States and the Netherlands.

	Cash and cash equivalents in the United States are maintained at financial institutions and, at times, balances may exceed federally insured limits. All non-interest bearing cash balances were fully insured to $250,000 per depositor at each financial institution, and noninterest bearing cash balances may again exceed federally insured limits.

	Cash and cash equivalents in The Netherlands are maintained at a financial institution and, at times, balances may exceed insured limits. Insurance coverage is limited to 100.000€ for all company accounts at each financial institution.

	Inventory

	Inventory is reported at the lower of cost or market value. The Company analyzes its inventory and writes down inventory that has become obsolete, or has a cost basis in excess of its expected net realizable value and inventory quantities in excess of expected requirements. Inventory primarily consists of a product used in creating vaccines using the OncoVAX® technology platform to be utilized in the planned Phase IIIb clinical trial and for research and development activities.

	Property and Equipment

	Property and equipment are recorded at cost and are depreciated or amortized over their estimated useful lives using the straight-line method. Estimated useful lives are as follows:


	Machinery and equipment		3 – 5 years
	Automobile		3 – 5 years
	Furniture and fixtures		5 years
	Computers and software		3 years

	Maintenance and repairs are charged to expense as incurred. Major betterments and improvements, which extend the useful life of the underlying assets, are capitalized and depreciated.

	Intangible Assets

	Intangible assets consist primarily of the cost of acquired patents associated with OncoVAX® to be used in research and development and the commercialization of cancer related vaccines. The Company has capitalized the cost of the acquired patents because the Company has identified alternative future research and development efforts for numerous forms of cancer which it intends to pursue and for which management believes will result in commercialization of related vaccines. Acquired patents are carried at cost less accumulated amortization. Amortization is calculated on a straight-line basis, over the estimated useful economic life of the patent, which is 12.3 years for OncoVAX®.

	Impairment of Long-Lived Assets

	Long-lived assets, including identifiable intangible assets with finite lives, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. The Company has determined that no impairment has occurred as of March 31, 2014.

	Foreign Currency Translation

	The financial statements of foreign subsidiaries are maintained in their functional currency, which generally is the local currency. The assets and liabilities are translated to U.S. dollars using the exchange rate in effect at the balance sheet date. Revenues, expenses and cash flows of these operations are translated using average exchange rates during the reporting period which they occur. The resulting translation adjustments are reflected in other comprehensive loss. As of March 31, 2014 and 2013 the assets of Vaccinogen BV, excluding intercompany balances, were approximately $252,000 and $263,000 respectively. For the three months ended March 31, 2014 and 2013 net deficit of Vaccinogen BV, excluding intercompany balances, was approximately $253,000 and $314,000, respectively. The net loss of Vaccinogen BV was approximately $349,000 and $387,000 for the three months ended March 31, 2014 and 2013 respectively.

	Revenue Recognition

	To date, the Company has not earned any revenues as the use of OncoVAX® to create cancer related vaccines still requires additional clinical trials and has not received regulatory approval for commercialization and sale.

Research and Development Expense

Research and development costs are expensed as incurred. Research and development expenses primarily include the amortization of intangible assets, cost of conducting clinical trials, compensation and related overhead for employees, consultants, facilities costs and the cost of materials purchased for research and development.

Stock-Based Compensation

The Company measures the cost of employee services received in exchange for stock options or restricted stock awards based upon the fair value of the award on the date of the grant. The Company recognizes the estimated grant date fair value of the award as stock-based compensation expense on a straight-line basis over the requisite service period, which is generally the vesting period.

The Company initially measures the cost of awards granted to non-employees based on the fair value of the award on the date of grant however such cost is re-measured at the end of each reporting period until performance is fully satisfied or services are rendered by the non-employee.

The fair value of stock options granted is calculated using the Black-Scholes option-pricing model, which requires the use of subjective assumptions including volatility, expected term, risk-free rate, and the fair value of the underlying common stock. The fair value of non-vested stock awards is determined based upon the estimated fair value of the Company's common stock.

Income Taxes

Deferred income tax assets and liabilities are determined based on differences between the financial statements and tax basis of assets and liabilities, as measured using the enacted tax rates, which are expected to be in effect when the differences reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. A full valuation allowance was recorded against its deferred tax assets of approximately $19 million and $18 million for the periods ended March 31, 2014 and December 31, 2013 respectively.

As required under ASC 740-270 Interim Financial Reporting, the Company has estimated its annual effective tax rate for the full fiscal year and applied that rate to its income tax before income taxes in determining its provision for income taxes for the three month period ended March 31, 2014. The Company had no provision for income taxes for the three months ended March 31, 2014.

The tax effects of uncertain tax positions are recognized in the financial statements only if the position is more likely than not to be sustained on audit, based on the technical merits of the position. For tax positions meeting the more likely than not threshold, the amount recognized in the consolidated financial statements is the largest benefit that had greater than 50% likelihood of being realized. Management has not identified any uncertain tax positions with the exception of income tax return filing penalties and accordingly has established a liability of $130,000 under ASC 740-10 (“FIN 48”) as of March 31, 2014 and December 31, 2013. It is the Company’s accounting policy to account for ASC 740-10 related penalties and interest in other liabilities/expenses and not include it in the income tax provision of consolidated statements of operations. The Company has identified its U.S. Federal income tax return, its state return in Maryland and Netherlands corporate income tax returns as its major tax jurisdictions. Tax returns for fiscal years 2007 and forward are still open for examination.

Financial Instruments

Warrants Accounted for as Liabilities

Abell Warrants

In October 2011, the Company entered into a borrowing arrangement with The Abell Foundation (“Abell”). In connection with that arrangement, the Company also issued warrants (the “Abell Warrants”) exercisable into common stock of the Company. In February 2012, the Company and Abell amended the agreement to provide for additional borrowings (the “Abell Loan”). In January 2013, the maturity of the Abell Loan was extended to March 31, 2013. In April 2013, the borrowing arrangement was further amended to extend the maturity date to May 31, 2013. On May 31, 2013, the borrowing arrangement was amended to extend the maturity date to July 31, 2013. During September 2013 the borrowing arrangement was amended effective July 31, 2013 to extend the maturity date to December 31, 2013. During January 2014 the borrowing arrangement was amended effective January 1, 2014 to extend the maturity date to January 31, 2104. During March 2014 the borrowing arrangement was amended effective February 1, 2014 to extend the maturity date to July 31, 2014. The accounting treatment of these extensions are described within Note 8 to these unaudited condensed consolidated financial statements. In connection to our promissory note issued to The Abell Foundation, we granted The Abell Foundation a security interest in our patents related to OncoVAX®.

The number of shares issuable pursuant to the Abell Warrants was originally determined based upon a fixed amount of $500,000 divided by 85% of the per share price of stock sold in the next qualifying round of venture capital financing (defined as a round that raised at least $20 million). In connection with February 2012 amendment to the borrowing arrangement, the fixed amount used to determine the ultimate number of shares into which the Abell Warrants are exercisable was increased to $800,000. In connection with the January 2013 amendment to the borrowing arrangement, the fixed amount used to determine the ultimate number of shares into which the Abell Warrants are exercisable was increased to $1.1 million and the total proceeds of the next qualifying round of venture capital financing was increased to $35 million. There were no amendments to the Abell Warrants in connection with the April 2013 and May 2013 modifications to the Abell Loan. The Abell Warrants have a contractual term of 10 years and were fully vested upon issuance.

The Abell Warrants represent a fixed obligation that is to be settled through the issuance of a variable number of shares of the Company’s common stock. Consistent with the provisions of ASC Topic 480, Distinguishing Liabilities from Equity, the Company has concluded that the Abell Warrants should be accounted for as a liability. The Company is required to record the Abell Warrants at their estimated fair value at the end of each reporting period, with changes in the estimated fair value recorded in the unaudited condensed consolidated statements of operations as a component of Gain (Loss) on Financial Instruments.

As of March 31, 2014 and December 31, 2013, the estimated fair value of the Abell Warrants was $1,376,066 and $1,615,835, respectively. The Company recorded a gain of $239,769 and $123,001 representing the change in the fair value of the Abell Warrants for the three months ended March 31, 2014 and 2013, respectively.

Included in the change in the carrying value of the liability at March 31, 2013 is $275,813 representing the grant date fair value of the amended number of shares issuable in connection with the Abell Warrants pursuant to the January 2013 amendments to the Abell Loan. This amount has been included in the determination of the loss resulting from the deemed extinguishment of the Abell Loan triggered by the January 2013 amendments. The loss from the deemed extinguishment of the Abell Loan has been included as a component of Gain (Loss) on Financial Instruments in the accompanying unaudited condensed consolidated statements of operations.

Effective July 31, 2013, the Company and the Abell agreed to amend the Abell Note (the “July Amendment”). In connection with the July Amendment, the Company and Abell also amended the terms and conditions of the Warrant. In addition to the continuation of the “fixed for variable” feature, if the Company has not repaid the outstanding debt in full by specified dates between July 31, 2013 and December 31, 2013, the Company will be required to issue additional warrants for incremental shares (“Contingent Warrants”). More specifically, since the debt remained outstanding as of August 31, September 30, October 31, November 30 and December 31, the Warrant will be exercisable into the number of shares as described above plus an additional 20,000, 40,000, 60,000, 80,000 and 100,000 respectively. It is understood that the exercise price related to the Contingent Warrants will be the same as that for those warrants subject to the Fixed for Variable provisions – that is it will depend upon a value equal to 85% of the lowest price paid a qualified future raise of equity capital. The outstanding debt was not repaid in full by December 31, 2013 and all 300,000 warrants were issued to Abell.

Effective February 1, 2014 the Company and Abell agreed to amend the Abell Note. In connection with the issuance of the Seventh Amended and Restated Promissory Note, we entered into an Amendment No. 7 to the Note and Warrant Purchase Agreement, which Agreement increases the amount of shares issuable to The Abell Foundation under the Warrant to be issued by up to 360,000 Warrant Shares (“Contingent Warrants”), calculated as follows: (i) an additional 60,000 Warrant Shares if the Note remains outstanding in whole or in part on March 1, 2014, (ii) an additional 60,000 Warrant Shares if the Note remains outstanding in whole or in part on April 1, 2014, (iii) an additional 60,000 Warrant Shares if the Note remains outstanding in whole or in part on May 1, 2014, (iv) an additional 60,000 Warrant Shares if the Note remains outstanding in whole or in part on June 1, 2014; (v) an additional 60,000 Warrant Shares if the Note remains outstanding in whole or in part on July 1, 2014 and (vi) an additional 60,000 Warrant Shares if the Note remains outstanding in whole or in part on July 31, 2014.

The outstanding debt was not repaid in full by March 31, 2014 and 120,000 warrants were issued to Abell. The warrants were valued using the Black-Scholes method, and for the three months ended March 31, 2014 approximately $794,000 was included in Interest expense.

The Contingent Warrants provide for the issuance of a fixed number of shares that are known at inception. The Contingent Share warrants are not considered a derivative as they are considered indexed to the Company’s own stock as defined by ASC 815-40.

Abell Investment Option

On January 16, 2013, the Company entered into an investment agreement with Abell under which Abell was granted an option to acquire up to $5.0 million of common stock of the Company (the “Abell Option”). The number of shares to be issued will be based on the lowest price paid by any purchaser of shares in a subsequent round of equity financing meeting certain conditions defined in the agreement. The term of the agreement and Abell’s right to exercise is perpetual.

The Abell Option represents a fixed obligation that is to be settled through the issuance of a variable number of shares of the Company’s common stock. Consistent with the provisions of ASC Topic 480, the Company has concluded that the Abell Option should be accounted for as a liability and should be recorded as the conditions necessary to trigger the holders rights to exercise are considered by management to be probable of occurring as of March 31, 2014. The Company is required to record the Abell Option at its estimated fair value at the end of each reporting period. The Company recorded the grant date fair value as a component of general and administrative expenses. Changes in the estimated fair value of the Abell Option will be recorded in the unaudited condensed consolidated statements of operations as a component of Gain (Loss) on Financial Instruments.

As of March 31, 2014, the estimated value of the Abell Option is $6,074,770 which the Company has recorded as a liability. The Company has classified the carrying value of the Abell Option in Financial instruments in the accompanying unaudited condensed consolidated balance sheet. The Company has recorded a gain of $1,317,758 and $0 for the three months ended March 31, 2014 and 2013 respectively, representing the change in the fair value of the Abell Option. The initial value assigned to the Abell Option of $5,954,545 was recorded as a component of General & Administrative expense in the accompanying unaudited condensed consolidated financial statements for the three months ended March 31, 2013.

Derivative Financial Instruments

The Company may enter into transactions that represent free-standing or embedded derivative financial instruments as those terms are defined in ASC Topic 815 Derivatives and Hedging (“Topic 815”). The Company records the estimated fair value of derivative financial instruments in its consolidated balance sheets and records changes in the estimated fair value of derivative financial instruments as income or expense in its unaudited condensed consolidated statements of operations.

Round C Warrants

From October 2012 through December 2013 and then again from January 2014 through March 31, 2014, the Company issued warrants to certain investors in the common stock of the Company (the “Round C Warrants”). Round C Warrants to acquire 339,966 shares of common stock were issued through December 2013 and Round C Warrants to acquire 130,389 shares of common stock were issued during the three months ended March 31, 2014. The Round C Warrants have an exercise price of $6.05, a contractual term of 5 years and were fully vested upon issuance.

The terms of the Round C Warrants provide for "down-round" anti-dilution adjustments in certain situations whereby the Company sells or issues (a) stock at a price per share less than the exercise price of the Round C Warrants or (b) equity linked financial instruments with an exercise price less than the exercise price of the Round C Warrants. Consistent with the provisions of ASC Topic 815-40, the Round C Warrants are classified as derivative financial instruments. The Company is required to record the estimated fair value of derivative financial instruments at the end of each reporting period, with changes in the estimated fair value of such derivatives recorded in the unaudited condensed consolidated statements of operations as a component of Gain (Loss) on Financial Instruments.

As of March 31, 2014 and December 31, 2013, the estimated fair value of the liability associated with the Round C Warrants was $1,998,481 and $1,796,427, respectively, and is included in Financial Instruments in the accompanying condensed consolidated balance sheets. The Company has recorded a gain of $375,296 and $44,617 representing the change in the fair value of the Round C Warrants for the three months ended March 31, 2014 and 2013 respectively.

2012 Bridge Loan

Between April 2012 and October 2012, the Company entered into transactions with various investors which resulted in the Company raising $1,019,000 from the issuance of unsecured notes payable (collectively the “Bridge Loan”). The Bridge Loan has no contractual maturity date, and is repayable only in the event that the Company closes on a future round of equity financing which results in gross proceeds of at least $20 million. If the Company fails to raise sufficient additional capital, there is no obligation to pay interest or repay any amount borrowed under the Bridge Loan. Should the Company be successful in raising sufficient equity capital, the Company must repay an amount to the investors equal to 2 times the amount originally raised.

The Company has classified the Bridge Loan as a derivative financial instrument, as it meets three qualifying criteria of ASC Topic 815 Derivatives and Hedging (“Topic 815”) including the contractual terms whereby the Company can be required to settle its obligation under the Bridge Loan by transferring cash to investors if and only when sufficient additional capital is raised. As of March 31, 2014, and December 31, 2013, the estimated fair value of the liability associated with the Bridge Loan was $720,000 and $990,000 respectively, which has been recorded and included in financial instruments in the accompanying condensed consolidated balance sheets.

The change in the carrying value of the Bridge Loan includes a reduction of $270,000 representing the carrying value of the liability, as referenced in Note 9, related to those investors on the date of conversion. In April 2013, the board of directors authorized the Company to offer the investors in the 2012 Bridge Loan, the option to convert the amount otherwise due and payable to them in the event of a successful qualified offering, or $2,038,000, into common stock of the Company, at a per share price equal to that provided in the Round C common stock offering, or $5.50 per share plus 30% warrant coverage. In order to accommodate all Bridge Loan holders, the total dollar value of common stock issuable in the Round C offering was increased from $11 million to $13 million.

During 2013, certain investors in the Bridge Loan elected to convert their rights to receive cash under the Bridge Loan into shares of common stock and common stock warrants. The accounts for these investors were increased to 2 times the amount originally invested creating a loss on financial instruments as of December 31, 2013 of $93,800. As a result, the Company issued 170,540 shares of common stock to certain holders of the Bridge Loan that had elected to convert their rights into common stock of the Company and an additional 4,787 Adjustment Shares as discussed in Note 10 of these unaudited condensed consolidated financial statements. The Company also issued additional Round C Warrants exercisable into 51,159 shares of common stock of the Company, with an exercise price of $6.05 per share.

During the three months ended March 31, 2014, certain investors in the Bridge Loan elected to convert their rights to receive cash under the Bridge Loan into shares of common stock and common stock warrants. The accounts for these investors were increased to 2 times the amount originally invested creating a loss on financial instruments as of March 31, 2014 of $30,000. As a result, the Company issued 54,545 shares of common stock to certain holders of the Bridge Loan that had elected to convert their rights into common stock of the Company and an additional 1,530 Adjustment Shares as discussed in Note 10 of these unaudited condensed consolidated financial statements. The Company also issued additional Round C Warrants exercisable into 16,363 shares of common stock of the Company, with an exercise price of $6.05 per share.

The Company has recorded a loss of $30,000 and $305,700 representing the change in the fair market carrying value of the Bridge Loan for the three months ended March 31, 2014 and 2013 respectively. This loss has been classified in Gain (Loss) on Financial Instruments in the accompanying unaudited condensed consolidated statements of operations.

Net Loss Per Share

Basic loss per share is determined by dividing loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted loss per share is computed by dividing the loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company's outstanding stock warrants, unvested restricted stock and the if-converted method is used to determine the dilutive effect of convertible preferred stock and convertible debt. The following common stock equivalents were excluded in the calculation of diluted loss per share because their effect would be anti-dilutive:

Three months ended March 31,		2014		2013

Stock Option Pool			77,000		-
Abell Investment Option			934,579		1,136,364
Convertible debt			76,923		91,324
Restricted stock awards			134,278		119,734
Warrants			3,575,948		2,780,906

Agreements_with_Intracel

Agreements with Intracel	3 Months Ended
Agreements with Intracel	Mar. 31, 2014
Agreement [Abstract]	'
Agreement [Text Block]	'
	4. Agreements with Intracel

	License Agreement

	On October 10, 2007, the Company entered into an agreement (the “License Agreement”) with Intracel Holdings Corporation (“Intracel”), for the exclusive and indefinite rights to license and use the OncoVAX® technology platform. OncoVAX® is an active specific immunotherapy (“ASI”) that uses the patient’s own cancer cells to block the return of cancer following surgery. In exchange for the rights to OncoVAX®, the Company (i) agreed to issue equity securities equal to 10% of the fully diluted capitalization of the Company, (ii) assumed liabilities of Intracel to Organon Teknika Corporation (“Organon”) totaling $4.0 million under an October 31, 2007 Letter Agreement between Intracel and Organon, (iii) agreed to pay $450,000 in cash for settling trade payable related to the OncoVAX intellectual property, and (iv) agreed to make royalty payments to Intracel based on future sales of OncoVAX®. The terms of the securities issued to Intracel provided Intracel with anti-dilution rights with respect to its 10% ownership interest (See Note 10). The License Agreement also contained a provision such that if the Company obtained specified levels of financing in a specified time period, that title to OncoVAX® would transfer to the Company without further consideration. If the Company did not reach the specified levels of financing in the specified period of time, Intracel could cancel the License Agreement and could re-purchase the rights to OncoVAX®. The Company did not obtain the necessary financing in the period specified.

	In connection with the License Agreement, the Company issued 1,506,750 shares of common stock valued at approximately $984,000 and assumed liabilities with an estimated value of $4,450,000. The Company estimated the fair value of the liabilities assumed based upon their face amount as these liabilities were due currently and on demand.

	Asset Transfer Agreement and Stock Exchange Agreement

	As a result of the Company’s inability to raise the necessary capital under the License Agreement, the Company and Intracel negotiated amended terms to the License Agreement. On June 24, 2010, the Company and Intracel entered into the Asset Transfer Agreement pursuant to which the title to all of the intellectual property associated with OncoVAX® was transferred to the Company. Under the Asset Transfer Agreement, the Company also agreed to exchange the previously issued common stock and Series AA preferred stock representing a 10% interest in the Company for shares of its Series B preferred stock equal to a 20% interest in the Company on a fully diluted basis.

	The terms and conditions of the Series B preferred stock provided Intracel with anti-dilution rights with respect to its 20% ownership interest (See Note 10). In addition, the Company agreed that Intracel’s ownership position (and corresponding anti-dilution rights) would increase to 50% upon failure of the Company to meet certain defined milestones, which included but were not limited to, the Company attaining specified levels of additional financing.

	The Company accounted for the acquisition of the rights to the OncoVAX® technology platform under the License Agreement in 2007 and the Asset Transfer Agreement in 2010 as an asset acquisition in accordance with ASC Topic 805, Business Combinations. Furthermore, as described in Note 2 to these consolidated financial statements, and in accordance with ASC Topic 730, Research and Development, the Company has capitalized the cost of acquiring the rights to OncoVAX® technology platform as these rights represent intangible assets to be used in research and development activities and for which future alternative uses exist.

	In June 2010, in connection with the Asset Transfer Agreement, the Company issued 3,452,766 shares of Series B preferred stock, with an estimated value of approximately $16.8 million. The Company estimated the fair value of the common stock issued pursuant to the License Agreement and the Series B Preferred Stock issued pursuant to the Asset Transfer Agreement by considering various commonly accepted valuation techniques, including the income and market approaches.

	The Company ultimately relied on the income approach, specifically, the discounted cash flow method, to estimate the value of the Company’s equity. The Company further utilized commonly used option pricing techniques to estimate the fair value of the various equity classes. The use of the income approach, and specifically the discounted cash flow method, requires management to make significant assumptions about the future level and timing of revenues, direct and indirect costs associated with continued research and development, the conduct of clinical trials, and the production and commercialization of the intended cancer vaccines. The discounted cash flow method also requires the estimation of discount rates used to reflect the risk inherent in the projected cash flows, the terminal growth rate, among other factors.

	The Company did not meet these milestones and consequently, in December 2010, was required to increase Intracel’s total ownership interest in the Company to 50% through the issuance of additional shares of Series B preferred stock.

	In December 2010, the Company issued 10,973,612 additional shares of Series B preferred stock to Intracel when the Company failed to meet certain conditions of the Asset Transfer Agreement. The estimated value of those additional shares of approximately $63.1 million was accounted for as additional consideration and is included in the total cost of acquiring the OncoVAX® technology platform.

	All shares of Series B preferred stock were converted to common stock in 2012 as discussed in Note 10 to these unaudited condensed consolidated financial statements.

	As of March 31, 2014 Intracel directly owns approximately 42% of the Company on a fully diluted basis, and certain officers and directors of Vaccinogen are also stockholders of Intracel and collectively own approximately 31% of the Company on a fully diluted basis. Intracel also continues to hold certain royalty rights associated with future commercial sales of vaccines developed using OncoVAX®.

Contingent_Equity_Lines_of_Cre

Contingent Equity Lines of Credit	3 Months Ended
Contingent Equity Lines of Credit	Mar. 31, 2014
Line of Credit Facility [Abstract]	'
Contingent Equity Lines Of Credit [Text Block]	'
	5. Contingent Equity Lines of Credit

	Initial Equity Line of Credit

	On July 18, 2012, the Company entered into an Investment Agreement (“Initial Investment Agreement”) with Kodiak Capital Group, LLC (“Kodiak”). The Investment Agreement provides the Company an equity line whereby the Company can issue and sell to Kodiak, from time to time, shares of the Company’s common stock up to an aggregate purchase price of $1.0 million (the “Initial Kodiak Shares”) during the Initial Open Period.

	On May 13, 2013 Vaccinogen and Kodiak Capital Group, LLC terminated the Initial Equity Line of Credit. The additional agreement with Kodiak discussed below was unaffected by this termination.

	Subsequent Equity Line of Credit

	On July 18, 2012, the Company entered into an Investment Agreement, as amended by that Amendment to Investment Agreement dated July 8, 2013 (“Subsequent Investment Agreement”) with Kodiak. The Subsequent Investment Agreement provides the Company an equity line (the “Subsequent Financing”) whereby the Company can issue and sell to Kodiak, from time to time, shares of the Company’s common stock up to an aggregate purchase price of $25 million (the “Subsequent Kodiak Shares”) during the Subsequent Open Period.

	The Subsequent Investment Agreement will terminate when any of the following events occur: (i) Kodiak has purchased an aggregate of $26 million of the Company’s common stock, (ii) on the date which is eighteen months (18) months following the original execution date of the Investment Agreement, or (iii) upon written notice from the Company to Kodiak. Similarly, this Subsequent Investment Agreement, may, at the option of the non-breaching party, terminate if Kodiak or the Company commits a material breach, or becomes insolvent or enters bankruptcy proceedings.

	As part of the consideration for the Financing, we paid Kodiak a document preparation fee of $25,000 and we issued Kodiak 236,364 shares of common stock valued at approximately $1.3 million. The Company concluded that it was more likely than not the Kodiak Equity Line would not be used at December 31, 2013 and subsequently the Investment Agreement terminated on January 18, 2014 without us issuing or selling any shares to Kodiak. Therefore, the consolidated financial statements for the year ended December 31, 2013 reflect the approximately $1.3 million as an expense, classified within General and Administrative expenses.

Property_and_Equipment

Property and Equipment	3 Months Ended
Property and Equipment	Mar. 31, 2014
Property, Plant and Equipment, Net [Abstract]	'
Property, Plant and Equipment Disclosure [Text Block]	'
	6. Property and Equipment

	Property and equipment consisted of the following:

	Period ended	March 31, 2014		December 31, 2013

	Machinery and equipment	$	904,631	$	903,964
	Furniture and fixtures		35,690		35,690
	Computers and software		1,929		1,929
			942,250		941,583

	Less accumulated depreciation		-752,297		-742,793

		$	189,953	$	198,790

	Depreciation expense was $9,504 and $7,356 for the three months ended March 31, 2014 and 2013, respectively.

Intangible_Assets

Intangible Assets	3 Months Ended
Intangible Assets	Mar. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Intangible Assets Disclosure [Text Block]	'
	7. Intangible Assets

	Intangible assets consist of the capitalized costs associated with the acquisition of patents related to OncoVAX® (the “Intellectual Property”) and the costs associated with website development and domain names.

	As discussed in Note 4 to these unaudited condensed consolidated financial statements, the total purchase price for the Intellectual Property was ultimately determined based upon the estimated fair value of the Series B preferred stock representing a 50% stock ownership in the Company, the value of cash payments made of $450,000 and, obligations of Intracel assumed of $4 million.

	Intangible assets by major asset class were as follows at March 31, 2014:

		Gross Carrying		Accumulated		Net Carrying
		Amount		Amortization		Amount

	Intellectual Property	$	84,481,856	$	23,467,070	$	61,014,786
	Other Intangible Assets		121,944		86,988		34,956

		$	84,603,800	$	23,554,058	$	61,049,742

	Intangible assets by major asset class were as follows at December 31, 2013:

		Gross Carrying		Accumulated		Net Carrying
		Amount		Amortization		Amount

	Intellectual Property	$	84,481,856	$	21,792,439	$	62,689,417
	Other Intangible Assets		121,944		85,802		36,142

		$	84,603,800	$	21,878,241	$	62,725,559

	The amortization expense for intangible assets was approximately $1.7 million and $1.7 million for the three months ended March 31, 2014 and 2013, respectively. The weighted average amortization period for intangible assets was 12.6 years.

	The estimated future amortization relating to all intangible assets that are recorded in the consolidated balance sheets as of March 31, 2014 is as follows:

	Years ending December 31,

	2014	$	5,022,713
	2015		6,698,530
	2016		6,698,530
	2017		6,698,530
	2018		6,698,530
	Thereafter		29,232,909
		$	61,049,742

Notes_Payable

Notes Payable	3 Months Ended
	Mar. 31, 2014
Notes Payable [Abstract]	'
Short-term Debt [Text Block]	'
	8. Notes Payable

	Notes payable are as follows:

		March 31, 2014		December 31, 2013

	Organon Obligation	$	3,500,000	$	3,500,000
	Abell Loan		903,803		1,331,217

		$	4,403,803	$	4,831,217

	Organon Obligation

	Organon, currently owned by Merck & Co, Inc., manufactures a key component used with the OncoVAX® technology. In 2007, in conjunction with the Agreement with Intracel, the Company assumed $4.0 million of related liabilities from Intracel due to Organon (“Organon Obligation”). Of the $4.0million due to Organon, $500,000 was paid at the time of the Agreement. The remaining $3.5 million was due in installments with an additional $500,000 (plus accrued interest) payable the first year but no later than one year after the agreement date of October 31, 2007. Organon may elect to receive this first $500,000 installment in stock. Commencing one year after the earlier of the first marketing approval of OncoVAX® by the United States Food and Drug Administration or the European Medicines Agency or October 31, 2007, Vaccinogen would make an annual payment of $1.0 million to Organon until repayment of the entire liability amount. The obligation accrued interest based on a simple annual interest rate based on the US prime lending rate in effect on the anniversary date of the agreement, or October 31, 2008, which was 4.00%. Interest expense under this agreement was approximately $35,000 for both the three months ended March 31, 2014 and March 31, 2013. The accrued interest on this obligation is shown on the Balance Sheet as a component of Accrued Interest. This obligation was secured by the OncoVAX® Intellectual Property. While the Company has not paid the installment due one year after the Agreement, no event of default has been declared by Organon or its successors including Merck & Co, Inc. Due to the right to declare an event of default and to accelerate all amounts owed on this obligation, all amounts owed under the Agreement have been classified as current in the accompanying condensed consolidated balance sheets. If an event of default were declared, the Company would need to pay the principal payment of $500,000 plus accrued interest, which as March 31, 2014 was approximately $128,000 within 45 days in order to cure such default.

	Abell Loan

	On October 26, 2011, the Company obtained a $1.5 million working capital loan from The Abell Foundation Inc. (“Abell”). The Abell Loan was originally due on April 26, 2012, with 8% simple interest accruing and payable on the maturity date. On February 16, 2012, Vaccinogen received an additional $300,000, thereby increasing the amount outstanding to $1.8 million. In January 2013, the maturity of the Abell Loan was extended to March 31, 2013. In April 2013, the borrowing arrangement was further amended to extend the maturity date to May 31, 2013. On May 31, 2013, the borrowing arrangement was amended to extend the maturity date to July 31, 2013, at which time all principal plus accrued interest is due in full. During September 2013 the borrowing arrangement was amended effective July 31, 2013 to extend the maturity date to December 31, 2013. In connection to our promissory note issued to The Abell Foundation, we granted The Abell Foundation a security interest in our patents related to OncoVAX®.

	The 2012 amendment to the Abell Loan was accounted for as a modification, the January 2013 amendment was accounted for as an extinguishment, and the April 2013, May 2013 and July 2013 amendments were accounted for as modifications, as those terms are defined under ASC Topic 470-50,

	Debt, Modifications and Extinguishments.

	No costs or expenses were incurred by the Company in connection with the April 2013 or May 2013 extensions. The July amendment requires for the issuance of a fixed number of shares at various points in time known as Contingent Share Warrants. The Contingent Share Warrants are not considered a derivative as they are considered indexed to the Company’s own stock as defined by ASC 815-40. As a result, the value assigned to the Contingent Share Warrants has been classified within stockholders’ equity. The outstanding debt was not repaid in full December 31, 2013 and 300,000 warrants were issued to Abell. The warrants were valued using the Black-Scholes method, and for the year ending December 31, 2013 approximately $1.7 million was included in interest expense.

	Effective January 1, 2014 the maturity date was extended to January 31, 2014. No costs or expenses were incurred by the Company in connection with the January amendment.

	On February 26, 2014, we issued a Seventh Amended and Restated Promissory Note to The Abell Foundation, Inc. dated February 1, 2014 in the aggregate principal amount of $1,038,957. The amended and restated note extends the maturity date until July 31, 2014. In addition, the amended and restated note provides that the note will be paid concurrently with the closing of each issuance or sale of additional shares of capital stock, or securities directly or indirectly convertible or exchangeable for capital stock (each an “Equity Issuance”) occurring after February 1, 2014 in an amount equal to (a) twenty-five percent (25%) of the next $5,693,135 of gross proceeds of such Equity Issuance(s), and (b) one hundred percent (100%) of the net proceeds of all Equity Issuance(s) thereafter.

	In connection with the issuance of the Seventh Amended and Restated Promissory Note, we entered into an Amendment No. 7 to the Note and Warrant Purchase Agreement (the “Amended Purchase Agreement”), which Amended Purchase Agreement increases the amount of shares issuable to The Abell Foundation under the Warrant to be issued to Abell by up to 360,000 Warrant Shares (the “Additional Warrant Shares”), calculated as follows: (i) an additional 60,000 Warrant Shares if the Note remains outstanding in whole or in part on March 1, 2014, (ii) an additional 60,000 Warrant Shares if the Note remains outstanding in whole or in part on April 1, 2014, (iii) an additional 60,000 Warrant Shares if the Note remains outstanding in whole or in part on May 1, 2014, (iv) an additional 60,000 Warrant Shares if the Note remains outstanding in whole or in part on June 1, 2014; (v) an additional 60,000 Warrant Shares if the Note remains outstanding in whole or in part on July 1, 2014 and (vi) an additional 60,000 Warrant Shares if the Note remains outstanding in whole or in part on July 31, 2014.

	The Additional Warrant Shares are not considered a derivative as they are considered indexed to the Company’s own stock as defined by ASC 815-40. As a result, the value assigned to the Additional Warrant Shares has been classified within stockholders’ equity.

	Payments of amounts due are required prior to the maturity date based on a percentage of proceeds received from the Company’s subsequent equity financing transactions, as outlined in the agreement. The Abell Loans are secured by all accounts, chattel paper, deposit accounts, equipment, general intangibles, instruments, inventory, investment property and letter of credit rights.

	Under the terms of the loan, in the event of default, the interest rate increases to 10% per annum. The Company recorded interest expense related to the Abell Loan of approximately $22,000 and $36,000 for the three months ended March 31, 2014 and 2013, respectively.

	As described in Note 3 to these unaudited condensed consolidated financial statements, in connection with the Abell Loan and the various amendments, the Company issued the Abell Warrants which are exercisable into common stock of the Company. The number of shares into which the Abell Warrants are exercisable was revised with each amendment to the Abell Loan and is ultimately equal $1.1 million divided by 85% of the purchase price per share of stock sold in the Company’s next venture capital financing resulting in proceeds of not less than $35.0 million.

	The fair value of the Abell Warrants issued in connection with the Abell Loan in 2011 and subsequent amendment in February 2012 were recorded upon issuance as a debt discount based upon the estimated fair value and were amortized as additional interest expense through the original maturity date.

	The fair value of the Abell Warrants issued in connection with the January 2013 amendment to the Abell Loan of $275,813 were included in the determination of the loss associated with the deemed extinguishment of the Abell Loan at that time. That loss was been classified within Loss on Financial instruments in the unaudited condensed consolidated statements of operations for the three months ended March 31, 2013.

	The fair value of the warrants issued under the February 2014 Amendment No. 7 to the Note and Warrant Purchase Agreement was charged to interest expense was approximately $794,000 for the three months ended March 31, 2014.

Fair_Value_Measurements

Fair Value Measurements	3 Months Ended
Fair Value Measurements	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Disclosures [Text Block]	'
	9. Fair Value Measurements

	Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction occurring in the most advantageous market. The Company determines fair value based on a hierarchy that priorities valuation techniques used to measure fair value based on observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources. Unobservable inputs reflect assumptions based on the best information available.

	The three levels of the fair value hierarchy are:

		Level 1 —	Inputs are quoted prices for identical assets or liabilities in an active market

		Level 2 —	Inputs include quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (interest rates and yield curves), and inputs that are derived principally from or corroborated by observable market data correlation or other means

		Level 3 —	Inputs that are unobservable and significant to the fair value measurement

	The Company is required to record or disclose the fair value of certain assets and liabilities. The fair value guidance described above is used in measuring and recording the fair value of the liability associated with the Abell Warrants, and the fair value of the financial derivatives including the Round C Warrants and the Bridge Financing. This fair value guidance also applies to the disclosure of the fair value of financial instruments not otherwise recorded in the Company’s condensed consolidated balance sheets at fair value.

	The Company’s financial instruments measured on a recurring basis using fair value estimates are as follows:

						March 31, 2014
	Description		Total			Level 1		Level 2			Level 3

	Abell Warrants		$	1,376,066		$	-	$	-		$	1,376,066
	Round C Warrants			1,998,481			-		-			1,998,481
	Bridge Loan			720,000			-		-			720,000
	Abell Investment Option			6,074,770			-		-			6,074,770

			$	10,169,317		$	-	$	-		$	10,169,317

						December 31, 2013
	Description		Total			Level 1		Level 2			Level 3

	Abell Warrants		$	1,615,835		$	-	$	-		$	1,615,835
	Round C Warrants			1,796,427			-		-			1,796,427
	Bridge Loan			990,000			-		-			990,000
	Abell Investment Option			7,392,528			-		-			7,392,528

			$	11,794,790		$	-	$	-		$	11,794,790

	The following is a reconciliation of the fair value measurements from December 31, 2013 to March 31, 2014.

			Abell			Round C		Bridge			Abell
			Warrants			Warrants		Loan			Option

	Balance, December 31, 2013		$	1,615,835		$	1,796,427	$	990,000		$	7,392,528
	Issuance of securities			37,529			577,350		-300,000			-
	Fair value change included in earnings			-277,298			-375,296		30,000			-1,317,758

	Balance, March 31, 2014		$	1,376,066		$	1,998,481	$	720,000		$	6,074,770

	The following is a reconciliation of the fair value measurements from December 31, 2012 to March 31, 2013.

			Abell			Round C		Bridge			Abell
			Warrants			Warrants		Loan			Option

	Balance, December 31, 2012		$	831,806		$	230,349	$	1,528,500		$	-
	Issuance of securities			275,813			169,024		-			5,954,545
	Fair value change included in earnings			-123,001			-44,617		305,700

	Balance, March 31, 2013		$	984,618		$	354,756	$	1,834,200		$	5,954,545

	Quantitative Information

	Quantitative information as of March 31, 2014 with respect to financial instruments measured and carried at fair value on a recurring basis with the use of significant unobservable inputs (Level 3) are as follows:

	Level 3 - Significant Unobservable Inputs

					Principal Valuation		Unobservable	Range
Description		Fair Value			Techniques		Inputs	(Weighted Average)

Abell Warrants		$	1,376,066		Black -Scholes		Strike price Equity volatility	N/A

Round C Warrants		$	1,998,481		Black -Scholes		Strike price Equity volatility	N/A

Bridge Loan		$	720,000		Present Value		Timing and amount of future cash flows	N/A

Abell Investment Option		$	6,074,770		Black -Scholes		Strike price Equity volatility	N/A

Abell Warrants and Round C Warrants
The fair value of the Abell Warrants and the Round C Warrants are estimated at the end of each reporting period using an option pricing model. More specifically, the Black-Scholes option pricing model was utilized in the valuation of both the Abell Warrants and the Round C Warrants. The following assumptions were used:

			Abell Warrants							Round C Warrants
Three months ended March 31,			2014				2013			2014			2013

Volatility			85%				80%			85%			90%
Exercise price			$4.55				$4.68			$5.88			$6.05
Stock price at March 31			$6.50				$5.42			$6.50			$5.42
Risk free interest rate			2.66% - 2.77%				1.58% - 1.83%			1.12% - 1.73%			0.66- 0.73%
Dividend yield			0%				0%			0%			0%
Expected life			10				10			3.7 -5.0			4.6 – 5.0

As described in Note 3 to the unaudited condensed consolidated financial statements, the exercise price of the Abell Warrants is ultimately dependent upon the per share price and size of future rounds of equity financing. The Black-Scholes option pricing model was used to value the Abell Warrants as management believes that it can reasonably estimate the terms and conditions of future equity offerings that would impact the valuation of the Abell Warrants. Management’s ability to estimate these terms is based in part upon the terms and conditions of binding agreements to raise future equity capital in place at the time of each valuation.

As described in Note 3 to the unaudited condensed consolidated financial statements, the Round C Warrants include a form of anti-dilution protection that may result in future adjustments to the terms of the warrants.

The fair value calculations include the use of both observable and estimated inputs. There remains an inherent subjectivity in the development of the strike price used for both the Abell and Round C warrants. Therefore, the Company considers the derived fair value to have been determined using Level 3 inputs.

Significant changes to the assumptions used in the Company’s model would result in changes in the fair value of the Abell Warrants and the Round C Warrants.

Abell Option

As described in Note 3 to these unaudited condensed consolidated financial statements, the number of shares issuable under the Abell Option is dependent upon the lowest price paid for shares in a future qualified round of equity financing. Management has valued the Abell Option based upon an estimate of the fair value of the Company’s underlying stock because management believes it can reasonably estimate the occurrence and the terms of the future equity offering necessary to trigger Abell’s right to exercise the option and establish an exercise price, and because the right to exercise the option has no expiration. Given the perpetual exercise right, the Company believes it is reasonable to consider the shares issuable under the Abell Option as common stock equivalents.

As of January 16, 2013, the date of issuance for the Abell Option, the Company reasonably expected the undiscounted common stock price issuable under the Subsequent Financing Agreement (see Note 5) to be $5.50 per share, discounted to $4.40 per share. Therefore, the $5 million investment divided by the discounted share price of $4.40 yielded an option for 1,136,364 shares. At March 31, 2014 and December 31, 2013, the estimated number of shares is 934,580 in recognition of the expected Venture Capital Financing price per share of $5.35, the effective price of the Round C issuances.

Since the Abell Option is perpetual, each option share has a value of the underlying common stock share or $6.50 and $7.91 per share as of March 31, 2014 and December 31, 2013 respectively. The Abell Option value will be adjusted at the end of each reporting period, based on the valuation of the underlying common stock. The change in value of the Abell Option will be recorded on the financial statements as a Loss on Financial Instruments.

The fair value calculations include the use of both observable and estimated inputs. There remains an inherent subjectivity in the development of the strike price used for the Abell Option. Therefore the Company considers the derived fair value to have been determined using Level 3 inputs.

Significant changes to the assumptions used in the Company’s model would result in changes in the fair value of the Abell Option.

Bridge Loan

The estimated fair value of the Bridge Loan was determined based upon the present value of probability weighted cash flows, using assumptions about the timing and amount of future cash flows and discount rates that management considers to be appropriate in the circumstances.

Because of the inherent subjectivity in management’s assumptions, the Company considers the derived fair value to have been determined using Level 3 inputs.

Significant changes to the assumptions used in the Company’s model would result in changes in the fair value of Bridge Loan.

Disclosure of the Fair Value of Financial Instruments

Cash and cash equivalents and accounts payable, are carried at amounts that approximate their fair values due to the short term nature of these financial instruments. The fair value of the Abell Loan approximates its carrying value due to the short term nature of the Abell Loan’s maturity. The fair value of the Organon Obligation approximates its carrying value as the note is due on demand.

Redeemable_Preferred_Stock_and

Redeemable Preferred Stock and Stockholders' Equity	3 Months Ended
Redeemable Preferred Stock and Stockholders' Equity	Mar. 31, 2014
Redeemable Preferred Stock and Stockholders' Equity [Abstract]	'
Redeemable Preferred Stock and Stockholder Equity [Text Block]	'
	10. Redeemable Preferred Stock and Stockholders’ Equity

	As of January 1, 2011, the aggregate number of shares which the Company was authorized to issue was 75,000,000 shares of common stock with par value of $.0001 per share and 50,000,000 shares of preferred stock. The Company designated 15,000,000 shares of preferred stock as Series AA Convertible Redeemable Preferred Stock with a par value of $.0001 per share (“Series AA”) and 35,000,000 shares of preferred stock as Series B Convertible Redeemable Preferred Stock with a par value of $.0001 per share (“Series B”).

	In August 2012, the Company amended and restated its Certificate of Incorporation to increase the number of shares authorized for issuance to 200,000,000 shares of common stock with a par value $.0001 and 50,000,000 shares of preferred stock with a par value of $.0001 per share.

	Common Stock

	On August 1, 2012, the Company issued 1,507,666 shares of common stock to the holders of the Series AA preferred stock in consideration for the conversion of all outstanding shares of Series AA preferred stock.

	On August 1, 2012, the Company issued 16,656,082 shares of common stock to the former holders of our Series B Preferred Stock in consideration for the conversion of all outstanding shares of Series B preferred stock.

	During 2012, the Company issued 236,364 shares of common stock to Kodiak in exchange for their commitment to enter into the equity financing agreements described in Note 5 to these consolidated financial statements. The Company estimated the fair value of the common stock issued to be approximately $1.3 million and has recorded that value as a deferred cost. These costs were to be offset against the anticipated proceeds of the equity financing agreements with Kodiak. The carrying value associated with these shares of common stock had been included in long-term prepaid expenses in the accompanying consolidated balance sheet as of December 31, 2012. The amount was written off as a General & Administrative expense on the accompanying financial statements for the year ended December 31, 2013 as is the agreement was expiring January 18, 2014 and it was determined that financing would not be probable prior to expiration.

	Round C Common Stock

	The subscription agreement for the Company’s most recent financing, beginning October 2012, through the issuance of common stock (“Round C”) provides a form of anti-dilution protection to subscribers. Pursuant to the subscription agreement, if the market price of the Company’s common stock on the effective date of the Company’s first S-1 registration statement filed with the SEC (the “Effectiveness Date Market Price”) is less than $5.50 per share, then the Company will issue to each subscriber additional shares of common stock. The number of shares issued would equal the difference between a) the number of shares that would have been issued if the price per unit was equal to the greater of the Effectiveness Date Market Price or $5.00 and b) the number of shares originally issued to the subscriber. The anti-dilution rights are determined to be clearly and closely related to the Round C common stock as that term is defined in Topic 815 and as a result these rights are not required to be accounted for as a free standing derivative financial instrument.

	During 2012, the Company raised additional capital of $920,002 through the issuance of 167,273 shares of common stock (Round C) and common stock warrants (Round C Warrants) to purchase 50,181 shares of common stock. $725,757 was allocated to the common stock and $194,245 was allocated to the common stock warrants. The common stock warrants were determined to be a derivative financial instrument. In addition, the Company satisfied a payable to a board member of the Company in the amount of $169,729 by issuing 30,860 shares of common stock and common stock warrants (Round C Warrants) exercisable into 9,258 shares of common stock. $133,624 was allocated to the common stock and $36,105 was allocated to the common stock warrants. The common stock warrants were determined to be a derivative financial instrument. The terms and conditions of the Round C Warrants are described in Note 3 to the unaudited condensed consolidated financial statements.

	The Company filed a Form S-1 Registration Statement with the SEC, which became effective on October 31, 2013. The Effectiveness Date Market Price of Vaccinogen stock as of that date was $5.35. Pursuant to the protection provided to subscribers prior to October 31, 2013, 27,213 Adjustment Shares were issued. All subscriptions subsequent to the October 31, 2013 effective date through December 31, 2013 have been issued Adjustment Shares, totaling 31,811 and 12,207 Adjustment Shares issued for the three months ended March 31, 2014. All of the Adjustment Shares are included in the calculation of total shares issued or outstanding for the periods ended March 31, 2014 and December 31, 2013.

	During 2013, the Company raised additional capital of $4,205,105 through the issuance of 764,578 shares of common stock (Round C), 21,465 Adjustment Shares and common stock warrants (Round C Warrants) to purchase 229,368 shares of common stock. $3,253,316 was allocated to the common stock;, $926,581 was allocated to the common stock warrants; $14,542 represents placement agent commissions paid and $10,746 was allocated to placement agent warrants. The Round C common stock warrants were determined to be a derivative financial instrument.

	During 2013, several investors in the Bridge Loan opted to convert their loan to equity in the amount of $937,970 and the Company issued 170,540 shares of common stock (Round C), 4.787 Adjustment Shares and common stock warrants (Round C Warrants) exercisable into 51,159 shares of common stock. $751,561 was allocated to the common stock and $186,409 was allocated to the common stock warrants. The common stock warrants were determined to be a derivative financial instrument. The terms and conditions of the Round C Warrants are described in Note 3 to the unaudited condensed consolidated financial statements.

	The Company has increased the size of the Round C Private Placement Offering to $23,038,000 (4,188,727 Units) (which may be increased to $28,030,000 (5,097,817 Units) at the discretion of the Company) and extended the Final Closing Date to July 31, 2014.

	Series AA Preferred Stock

	In 2010, the Company created a class of preferred stock known as Series AA preferred stock and authorized 15,000,000 shares for issuance as Series AA preferred stock. All shares of Series AA were issued with an original purchase price of $9.0797 per share (“Series AA Original Issuance Price”). From January 13, 2011 to October 24, 2011, the Company issued 123,015 shares of Series AA Preferred Stock to 15 third party investors in a private offering at a price of $9.0797 per share resulting in net proceeds of approximately $1.1 million after approximately $14,000 in related stock issuance costs. As noted above, all shares of Series AA were converted into common stock of the Company in 2012.

	Series B Preferred Stock

	In 2010, the Company created a class of preferred stock known as Series B preferred stock and authorized 35,000,000 shares for issuance as Series B Preferred Stock. All shares of Series B were issued pursuant to a Stock Exchange Agreement entered into concurrently with the June 2010 Asset Transfer Agreement with Intracel. As noted above, all shares of Series B were converted into common stock in 2012.

StockBased_Compensation

Stock-Based Compensation	3 Months Ended
Stock-Based Compensation	Mar. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	11. Stock-Based Compensation

	Restricted Stock

	The Company from time to time has issued shares of restricted common shares to directors. From August 2010 through March 31, 2014, the Company issued 134,278 shares of restricted common stock to employees whose vesting is contingent upon a successful initial public stock offering with a 10 year contractual life. In 2007 and 2010 the Company issued 180,000 and 1.1 million shares, respectively of restricted common stock to employees whose vesting is dependent upon future employment. Those shares generally vest over periods of 4 to 5 years.

	The Company records compensation expense for the award of restricted stock based upon the awards fair value determined as the difference in the estimated fair value of the Company’s common stock and the price paid by the employee, if any, generally on the date of grant. The fair value of restricted stock awards is recognized as compensation expense over the service period which is generally the same as the vesting period. No compensation cost has been or will be recognized for the restricted stock awards whose vesting is contingent upon a successful initial public offering until such event is probable of occurring. As of March 31, 2014, management has determined that such an event is not yet probable of occurring. No compensation expense related to awards with service based vesting was recorded for the three months ended March 31, 2014 and 2013

	The following table summarizes activity related to restricted-stock awards for the three months ended March 31, 2014 and 2013. The weighted average fair values for the awards below are based on the fair value at the grant date of the respective awards, which is equal to the value of the Company’s common stock on such date.

			2014						2013
	Three months ended March 31,		Shares			Weighted			Shares			Weighted
						Average						Average
						Fair Value						Fair Value

	Balance, January 1			134,278		$	3.91			119,734		$	3.42
	Granted			-			-			-			-
	Vested			-			-			-			-
	Forfeitures			-			-			-			-

	Balance, March 31			134,278		$	3.91			119,734		$	3.42

	As of March 31, 2014 and December 31, 2013, total unrecognized compensation costs related to nonvested restricted stock awards to purchase 134,278 shares of common stock was approximately $524,000 and $489,000 respectively, which will be recognized upon a successful initial public offering of the Company’s stock. The nonvested restricted stock awards have a weighted average remaining contractual term of 7.12 years as of March 31, 2014. No awards vested during the three months ended March 31, 2014 and 2013.

	In December 2010, the Company has committed to issue $462,500 of restricted stock, subject to restrictions yet to be defined, to an officer of the Company if and only if the Company completes a financing round that provides bona fide equity capital to the Company of at least $35.0 million.

	Stock Option Pool

	On July 17, 2012, the Company’s board of directors approved the grant of 200,000 options to acquire Vaccinogen common stock. No options were issued through December 31, 2012. On October 23, 2012, the Company committed to grant an option to purchase 20,000 shares of common stock to an employee if the Company’s stock begins trading on the “Over the Counter Bulletin Board”. The exercise price of the award will be equal to the Company’s stock closing price on the first day of trading on the “Over the Counter Bulletin Board” and the awards will vest over four years from that date.

	During the first quarter of 2013 option grant letters were sent to existing employees and consultants granting an option to purchase an additional 87,000 shares of common stock with the grant date being set as the first day of trading on the “Over the Counter Bulletin Board”. The exercise price of the award was equal to the Company’s closing price on the first day of trading and will vest over four years from that date.

	The Company uses the Black-Scholes option pricing model to calculate the fair value of options. The significant assumptions used in this model include:

	Annual Dividend		-
	Expected life (in years)		6.25 – 10.00
	Risk free interest rate		1.35% - 2.17%
	Expected volatility		80%

	The following table summarizes the Stock Option pool activity for the three months ended March 31, 2014. No Stock Options were granted as of March 31, 2013.

			Shares			Weighted Average				Weighted Average
			Shares			Exercise Price				Remaining Life
	Balance, January 1, 2014			77,000		$	7			3.45
	Granted			-			-			-
	Forfeited			-			-			-
	Balance, March 31. 2014			77,000		$	7			3.2

	During the three months ended March 31, 2014 and 2013 the Company recorded stock based compensation expense of $22,603 and $0 respectively. For the three months ended March 31, 2014, $4,777 was allocated to General & Administrative expense and $17,826 to Research & Development.

	Total compensation costs for unvested stock option awards outstanding at March 31, 2014 was approximately $353,000 to be recognized over approximately 3.2 years.

	Stock Purchase Warrants

	From time to time the Company has issued stock purchase warrants to non-employees in exchange for services rendered. As of March 31, 2014 and March 31, 2013, approximately 785,575 warrants were issued and outstanding with exercise prices ranging from $1.00 to $5.50. To date, all warrants have been issued for past services, with the exercise prices at least equal to the then estimated fair value of the underlying security, were fully vested upon issuance, and had contractual terms ranging from 2.5 to 7.5 years.

	The following table summarizes the stock purchase warrant activity for the three months ended March 31, 2014 and 2013.

			2014						2013
			Shares			Weighted			Shares			Weighted
						Average Fair						Average Fair
						Value						Value

Balance, January 1			785,575		$	1.48			785,575		$	1.48
Granted			-			-			-			-

Balance, March 31			785,575		$	1.48			785,575		$	1.48

The following table summarizes information on warrants outstanding as of March 31, 2014:

Exercise price		Shares		Weighted Average			Weighted Average
Exercise price		Shares		Remaining Life			Exercise Price

$1.00		705,575			0.8		$	1
$5.50		80,000			3.49		$	5.5

Total		785,575

Common Stock Warrants

The following table summarizes the warrant activity for the three months ended March 31, 2014 and is inclusive of the Abell Warrants, the Round C Warrants, the Stock Purchase Warrants and represents the total outstanding warrants.

		Shares			Weighted Average			Weighted Average
		Shares			Exercise Price			Remaining Life
Outstanding at January 1, 2014			3,310,378		$	2.2			2.95
Granted			265,570		$	5.35			7.41
Exercised			-			-			-
Expired			-			-			-
Outstanding at March 31, 2014			3,575,948		$	2.44			3.12

The warrants granted in the three months ended March 31, 2014 and 2013 had a weighted average fair value at grant date of $5.45 and $3.79 respectively.

The following table summarizes the outstanding warrants by year of expiration:

		Shares
2014			1,151,690
2015			1,201,475
2016			-
2017			139,439
2018			280,527
Thereafter			802,817
Total			3,575,948

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
Commitments and Contingencies	Mar. 31, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	12. Commitments and Contingencies

	Leases

	The Company leases office space, a manufacturing facility, and equipment under operating leases expiring in 2014. In addition, the Company leases storage facilities on a month to month basis. Rent expense was approximately $40,591 and $41,333 for the three months ended March 31, 2014 and March 31, 2013, respectively.

	Minimum future rental payments under non-cancelable operating leases, including amendments to leases entered through the date the financial statements were available to be issued, total $94,055 for 2014 and $20,968 for 2015 for a total of $115,023.

	Royalty Agreement with Intracel

	Pursuant to the Agreement, the Company agreed to pay Intracel the following royalties on the Net Sales of Royalty Bearing Products (as defined): (i) 3% of net sales on the first $350.0 million of Net Sales of Colon Cancer Products occurring in the calendar year; (ii) 4% of net sales of Net Sales of Royalty Bearing Products occurring in the calendar year in excess of $350.0 million and up to and including $750.0 million and (iii) 5% of net sales of Net Sales of Royalty Bearing Products occurring in the calendar year in excess of $750.0 million.

	Royalty Agreement with Organon

	The Company has agreed to pay Organon a royalty of 10% of the Net Sales of OncoVAX® (and all other TICE BCG related products, if any) until the Organon Obligation is paid in full, including interest, and 3% for 5 years thereafter.

	Litigation

	The Company may be subject to certain claims arising in the ordinary course of business. The Company and a vendor are in dispute over amounts owed for services performed. A demand for payment under a written agreement has been made against the Company in the amount of approximately $150,000. Management believes the vendor did not perform under the terms of the contract and contends that no amounts are due to the vendor. Management has offered to settle the matter for $75,000 to be paid upon the Company’s successful initial public offering and has accrued $75,000 in the accompanying unaudited condensed consolidated financial statements.

	VAT Taxes

	The foreign subsidiary of the Company, located in The Netherlands, was presented with a VAT tax bill for the years 2010 and 2011 in the amount of 65,666€. The Company is appealing the decision as we believe that we should be VAT exempt. There has not yet been a decision made by the Dutch authorities and there is no estimate of when a decision will be made. In the event an unfavorable decision is made, the Company will be required to pay the full amount plus interest. The original bill at the March 31, 2014 exchange rate would have a USD equivalent of approximately $90,000. There has been no expense accrued on the accompanying unaudited condensed consolidated financial statements.

Related_Party_Transactions

Related Party Transactions	3 Months Ended
Related Party Transactions	Mar. 31, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	13. Related Party Transactions

	On April 15, 2012, Intracel provided an unsecured note payable in the amount of $30,000. The note is unsecured, non-interest bearing, and becomes due on the date on which a minimum equity raise of $1.0 million occurs. The carrying value of the note payable to Intracel is included in related party payable in the accompanying unaudited condensed consolidated financial statements as of December 31, 2013. The note was paid in full during January 2014.

	In 2012, an executive of the Company loaned the Company $10,000. As of December 31, 2013, the balance due of $4,099 is past due and in default. The carrying value of this amount due to the Company executive is included in related party payable in the accompanying unaudited condensed consolidated financial statements as of December 31, 2013. The loan was paid in full during January 2014.

	As discussed in Note 10, on February 14, 2012, a member of the board of directors of the Company, agreed to loan the Company money to pay one of the Company’s vendors an outstanding amount of $169,729. The Company subsequently issued to this board member 30,860 shares of common stock and a warrant exercisable into 9,258 warrants (Round C Warrant).

	During 2013, an executive of the Company loaned the Company $70,000. As of December 31, 2013 $20,000 remained unpaid. The carrying value of this amount due to the Company executive is included in related party payable in the accompanying consolidated financial statements as of December 31, 2013. The loan was paid in full during January 2014.

Supplemental_Disclosure_of_Cas

Supplemental Disclosure of Cash Flow Information	3 Months Ended
Supplemental Disclosure of Cash Flow Information	Mar. 31, 2014
Supplemental Cash Flow Elements [Abstract]	'
Cash Flow, Supplemental Disclosures [Text Block]	'
	14. Supplemental Disclosure of Cash Flow Information

	For the three months ended March 31, 2014 and March 31, 2013 the Company paid interest costs of approximately $23,500 and $38,550, respectively.

	From January 1, 2014 through March 31, 2014 the Company raised additional capital totaling approximately $2.0 million (net of issuance costs) from the issuance of 375,399 shares of Round C Common Stock, 10,704 adjustment shares and additional Round C Warrants to purchase 112,663 shares of common stock. The Company allocated approximately $1.5 million of the total 2014 proceeds to the common stock and approximately $0.5 million of the total proceeds to the common stock warrants.

	From January 1, 2013 through March 31, 2013 the Company raised additional capital totaling approximately, $972,000 (net of issuance costs) from the issuance of 176,697 shares of Round C Common stock and additional Round C Warrants to purchase 53,008 shares of common stock. The Company allocated approximately $803,000 of the total 2013 proceeds to the common stock and approximately $169,000 of the total proceeds to the common stock warrants.

Subsequent_Events

Subsequent Events	3 Months Ended
Subsequent Events	Mar. 31, 2014
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	15. Subsequent Events

	In accordance with ASC 855-50, “Subsequent Events,” the Company has reviewed events through the date of the filing.

	April 1, 2014 through May 13, 2014, the Company raised additional capital totaling approximately $151,000 (net of issuance costs) through the issuance of 27,500 shares of Common Stock, warrants to purchase 250 shares of Common Stock and773 Adjustment Shares.

	The Chief Executive Officer has loaned the Company $28,500 during April 2014. This is a non interest bearing loan.

	On April 24, 2014, the Company entered into a binding agreement (the “Agreement”) with The Investment Syndicate, a group of investors (“TIS”), pursuant to which TIS has agreed to purchase (a) up to 3,636,364 units (“Units”), each Unit consisting of one share of our common stock and one warrant, exercisable for five years, to purchase three tenths (0.3) of a share of common stock at an exercise price of $6.05 per whole share, at $5.50 per Unit, for a total of $20,000,000, in our current Unit (Round C) offering, and (b) up to 10,909,091 shares of our common stock at $5.50 per share, for a total of up to an additional $60,000,000, all in up to five closings, with certain terms and conditions. TIS’ obligation to purchase any Units (or shares of common stock) under the Agreement is subject to the satisfaction of these closing conditions. There can be no assurance that any of these conditions will be met or that TIS will purchase any Units or common stock. A full description of this transaction is set forth in our Current Report on Form 8-K dated April 24, 2014 and filed with the SEC on April 28, 2014.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Basis of Accounting, Policy [Policy Text Block]	'
	Basis of Presentation

	The accompanying unaudited condensed consolidated financial statements as of March 31, 2014 and for the three months ended March 31, 2014 and 2013, respectively include the accounts of Vaccinogen, Inc. and its wholly owned subsidiary and have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) and, therefore, omit or condense certain disclosures and other information required under generally accepted accounting principles in the United States of America (“US GAAP”) for complete financial statements. These unaudited condensed consolidated financial statements should therefore be read in conjunction with the audited consolidated financial statements and the accompanying notes for the year ended December 31, 2013.

	In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all the adjustments and reclassifications necessary for a fair presentation for the periods presented in accordance with US GAAP. The results for the three months ended March 31, 2014 are not necessarily indicative of the results to be expected for the full year.

Consolidation, Policy [Policy Text Block]	'
	Principles of Consolidation

	The unaudited condensed consolidated financial statements include accounts of Vaccinogen and its wholly owned subsidiary, Vaccinogen BV (a company incorporated in the Netherlands). All intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates, Policy [Policy Text Block]	'
	Use of Estimates

	The preparation of unaudited condensed consolidated financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in its financial statements. On an ongoing basis, the Company evaluates the estimates used in recording common stock warrant related liabilities, derivative financial instruments, stock based compensation, and where applicable, the fair value of assets. The Company may base such estimates on various assumptions which it believes to be reasonable under the circumstances. Actual results could differ from those estimates.

Cash and Cash Equivalents, Policy [Policy Text Block]	'
	Cash and Cash Equivalents

	The Company considers all highly liquid securities with a maturity of three months or less at acquisition to be cash equivalents. Cash and cash equivalents include demand deposits with financial institutions and at times the amounts may exceed federally insured deposit limits. The Company has not experienced any losses and does not believe it is exposed to any significant credit risk related to demand deposits.

Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]	'
	Restricted Cash

	Restricted cash represents monies pledged by the Company’s foreign subsidiary for a lease obligation related to the manufacturing facility and to the Dutch government as required for companies with irradiator equipment.

Concentration Risk, Credit Risk, Policy [Policy Text Block]	'
	Concentrations of Credit Risk

	Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains its cash and cash equivalents with high-credit-quality financial institutions in the United States and the Netherlands.

	Cash and cash equivalents in the United States are maintained at financial institutions and, at times, balances may exceed federally insured limits. All non-interest bearing cash balances were fully insured to $250,000 per depositor at each financial institution, and noninterest bearing cash balances may again exceed federally insured limits.

	Cash and cash equivalents in The Netherlands are maintained at a financial institution and, at times, balances may exceed insured limits. Insurance coverage is limited to 100.000€ for all company accounts at each financial institution.

Inventory, Policy [Policy Text Block]	'
	Inventory

	Inventory is reported at the lower of cost or market value. The Company analyzes its inventory and writes down inventory that has become obsolete, or has a cost basis in excess of its expected net realizable value and inventory quantities in excess of expected requirements. Inventory primarily consists of a product used in creating vaccines using the OncoVAX® technology platform to be utilized in the planned Phase IIIb clinical trial and for research and development activities.

Property, Plant and Equipment, Policy [Policy Text Block]	'
	Property and Equipment

	Property and equipment are recorded at cost and are depreciated or amortized over their estimated useful lives using the straight-line method. Estimated useful lives are as follows:


	Machinery and equipment	3 – 5 years
	Automobile	3 – 5 years
	Furniture and fixtures	5 years
	Computers and software	3 years

	Maintenance and repairs are charged to expense as incurred. Major betterments and improvements, which extend the useful life of the underlying assets, are capitalized and depreciated.

Goodwill and Intangible Assets, Policy [Policy Text Block]	'
	Intangible Assets

	Intangible assets consist primarily of the cost of acquired patents associated with OncoVAX® to be used in research and development and the commercialization of cancer related vaccines. The Company has capitalized the cost of the acquired patents because the Company has identified alternative future research and development efforts for numerous forms of cancer which it intends to pursue and for which management believes will result in commercialization of related vaccines. Acquired patents are carried at cost less accumulated amortization. Amortization is calculated on a straight-line basis, over the estimated useful economic life of the patent, which is 12.3 years for OncoVAX®.

Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]	'
	Impairment of Long-Lived Assets

	Long-lived assets, including identifiable intangible assets with finite lives, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. The Company has determined that no impairment has occurred as of March 31, 2014.

Foreign Currency Transactions and Translations Policy [Policy Text Block]	'
	Foreign Currency Translation

	The financial statements of foreign subsidiaries are maintained in their functional currency, which generally is the local currency. The assets and liabilities are translated to U.S. dollars using the exchange rate in effect at the balance sheet date. Revenues, expenses and cash flows of these operations are translated using average exchange rates during the reporting period which they occur. The resulting translation adjustments are reflected in other comprehensive loss. As of March 31, 2014 and 2013 the assets of Vaccinogen BV, excluding intercompany balances, were approximately $252,000 and $263,000 respectively. For the three months ended March 31, 2014 and 2013 net deficit of Vaccinogen BV, excluding intercompany balances, was approximately $253,000 and $314,000, respectively. The net loss of Vaccinogen BV was approximately $349,000 and $387,000 for the three months ended March 31, 2014 and 2013 respectively.

Revenue Recognition, Policy [Policy Text Block]	'
	Revenue Recognition

	To date, the Company has not earned any revenues as the use of OncoVAX® to create cancer related vaccines still requires additional clinical trials and has not received regulatory approval for commercialization and sale.

Research and Development Expense, Policy [Policy Text Block]	'
	Research and Development Expense

	Research and development costs are expensed as incurred. Research and development expenses primarily include the amortization of intangible assets, cost of conducting clinical trials, compensation and related overhead for employees, consultants, facilities costs and the cost of materials purchased for research and development.

Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	'
	Stock-Based Compensation

	The Company measures the cost of employee services received in exchange for stock options or restricted stock awards based upon the fair value of the award on the date of the grant. The Company recognizes the estimated grant date fair value of the award as stock-based compensation expense on a straight-line basis over the requisite service period, which is generally the vesting period.

	The Company initially measures the cost of awards granted to non-employees based on the fair value of the award on the date of grant however such cost is re-measured at the end of each reporting period until performance is fully satisfied or services are rendered by the non-employee.

	The fair value of stock options granted is calculated using the Black-Scholes option-pricing model, which requires the use of subjective assumptions including volatility, expected term, risk-free rate, and the fair value of the underlying common stock. The fair value of non-vested stock awards is determined based upon the estimated fair value of the Company's common stock.

Income Tax, Policy [Policy Text Block]	'
	Income Taxes

	Deferred income tax assets and liabilities are determined based on differences between the financial statements and tax basis of assets and liabilities, as measured using the enacted tax rates, which are expected to be in effect when the differences reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. A full valuation allowance was recorded against its deferred tax assets of approximately $19 million and $18 million for the periods ended March 31, 2014 and December 31, 2013 respectively.

	As required under ASC 740-270 Interim Financial Reporting, the Company has estimated its annual effective tax rate for the full fiscal year and applied that rate to its income tax before income taxes in determining its provision for income taxes for the three month period ended March 31, 2014. The Company had no provision for income taxes for the three months ended March 31, 2014.

	The tax effects of uncertain tax positions are recognized in the financial statements only if the position is more likely than not to be sustained on audit, based on the technical merits of the position. For tax positions meeting the more likely than not threshold, the amount recognized in the consolidated financial statements is the largest benefit that had greater than 50% likelihood of being realized. Management has not identified any uncertain tax positions with the exception of income tax return filing penalties and accordingly has established a liability of $130,000 under ASC 740-10 (“FIN 48”) as of March 31, 2014 and December 31, 2013. It is the Company’s accounting policy to account for ASC 740-10 related penalties and interest in other liabilities/expenses and not include it in the income tax provision of consolidated statements of operations. The Company has identified its U.S. Federal income tax return, its state return in Maryland and Netherlands corporate income tax returns as its major tax jurisdictions. Tax returns for fiscal years 2007 and forward are still open for examination.

Fair Value of Financial Instruments, Policy [Policy Text Block]	'
	Financial Instruments

	Warrants Accounted for as Liabilities

	Abell Warrants

	In October 2011, the Company entered into a borrowing arrangement with The Abell Foundation (“Abell”). In connection with that arrangement, the Company also issued warrants (the “Abell Warrants”) exercisable into common stock of the Company. In February 2012, the Company and Abell amended the agreement to provide for additional borrowings (the “Abell Loan”). In January 2013, the maturity of the Abell Loan was extended to March 31, 2013. In April 2013, the borrowing arrangement was further amended to extend the maturity date to May 31, 2013. On May 31, 2013, the borrowing arrangement was amended to extend the maturity date to July 31, 2013. During September 2013 the borrowing arrangement was amended effective July 31, 2013 to extend the maturity date to December 31, 2013. During January 2014 the borrowing arrangement was amended effective January 1, 2014 to extend the maturity date to January 31, 2104. During March 2014 the borrowing arrangement was amended effective February 1, 2014 to extend the maturity date to July 31, 2014. The accounting treatment of these extensions are described within Note 8 to these unaudited condensed consolidated financial statements. In connection to our promissory note issued to The Abell Foundation, we granted The Abell Foundation a security interest in our patents related to OncoVAX®.

	The number of shares issuable pursuant to the Abell Warrants was originally determined based upon a fixed amount of $500,000 divided by 85% of the per share price of stock sold in the next qualifying round of venture capital financing (defined as a round that raised at least $20 million). In connection with February 2012 amendment to the borrowing arrangement, the fixed amount used to determine the ultimate number of shares into which the Abell Warrants are exercisable was increased to $800,000. In connection with the January 2013 amendment to the borrowing arrangement, the fixed amount used to determine the ultimate number of shares into which the Abell Warrants are exercisable was increased to $1.1 million and the total proceeds of the next qualifying round of venture capital financing was increased to $35 million. There were no amendments to the Abell Warrants in connection with the April 2013 and May 2013 modifications to the Abell Loan. The Abell Warrants have a contractual term of 10 years and were fully vested upon issuance.

	The Abell Warrants represent a fixed obligation that is to be settled through the issuance of a variable number of shares of the Company’s common stock. Consistent with the provisions of ASC Topic 480, Distinguishing Liabilities from Equity, the Company has concluded that the Abell Warrants should be accounted for as a liability. The Company is required to record the Abell Warrants at their estimated fair value at the end of each reporting period, with changes in the estimated fair value recorded in the unaudited condensed consolidated statements of operations as a component of Gain (Loss) on Financial Instruments.

	As of March 31, 2014 and December 31, 2013, the estimated fair value of the Abell Warrants was $1,376,066 and $1,615,835, respectively. The Company recorded a gain of $239,769 and $123,001 representing the change in the fair value of the Abell Warrants for the three months ended March 31, 2014 and 2013, respectively.

	Included in the change in the carrying value of the liability at March 31, 2013 is $275,813 representing the grant date fair value of the amended number of shares issuable in connection with the Abell Warrants pursuant to the January 2013 amendments to the Abell Loan. This amount has been included in the determination of the loss resulting from the deemed extinguishment of the Abell Loan triggered by the January 2013 amendments. The loss from the deemed extinguishment of the Abell Loan has been included as a component of Gain (Loss) on Financial Instruments in the accompanying unaudited condensed consolidated statements of operations.

	Effective July 31, 2013, the Company and the Abell agreed to amend the Abell Note (the “July Amendment”). In connection with the July Amendment, the Company and Abell also amended the terms and conditions of the Warrant. In addition to the continuation of the “fixed for variable” feature, if the Company has not repaid the outstanding debt in full by specified dates between July 31, 2013 and December 31, 2013, the Company will be required to issue additional warrants for incremental shares (“Contingent Warrants”). More specifically, since the debt remained outstanding as of August 31, September 30, October 31, November 30 and December 31, the Warrant will be exercisable into the number of shares as described above plus an additional 20,000, 40,000, 60,000, 80,000 and 100,000 respectively. It is understood that the exercise price related to the Contingent Warrants will be the same as that for those warrants subject to the Fixed for Variable provisions – that is it will depend upon a value equal to 85% of the lowest price paid a qualified future raise of equity capital. The outstanding debt was not repaid in full by December 31, 2013 and all 300,000 warrants were issued to Abell.

	Effective February 1, 2014 the Company and Abell agreed to amend the Abell Note. In connection with the issuance of the Seventh Amended and Restated Promissory Note, we entered into an Amendment No. 7 to the Note and Warrant Purchase Agreement, which Agreement increases the amount of shares issuable to The Abell Foundation under the Warrant to be issued by up to 360,000 Warrant Shares (“Contingent Warrants”), calculated as follows: (i) an additional 60,000 Warrant Shares if the Note remains outstanding in whole or in part on March 1, 2014, (ii) an additional 60,000 Warrant Shares if the Note remains outstanding in whole or in part on April 1, 2014, (iii) an additional 60,000 Warrant Shares if the Note remains outstanding in whole or in part on May 1, 2014, (iv) an additional 60,000 Warrant Shares if the Note remains outstanding in whole or in part on June 1, 2014; (v) an additional 60,000 Warrant Shares if the Note remains outstanding in whole or in part on July 1, 2014 and (vi) an additional 60,000 Warrant Shares if the Note remains outstanding in whole or in part on July 31, 2014.

	The outstanding debt was not repaid in full by March 31, 2014 and 120,000 warrants were issued to Abell. The warrants were valued using the Black-Scholes method, and for the three months ended March 31, 2014 approximately $794,000 was included in Interest expense.

	The Contingent Warrants provide for the issuance of a fixed number of shares that are known at inception. The Contingent Share warrants are not considered a derivative as they are considered indexed to the Company’s own stock as defined by ASC 815-40.

	Abell Investment Option

	On January 16, 2013, the Company entered into an investment agreement with Abell under which Abell was granted an option to acquire up to $5.0 million of common stock of the Company (the “Abell Option”). The number of shares to be issued will be based on the lowest price paid by any purchaser of shares in a subsequent round of equity financing meeting certain conditions defined in the agreement. The term of the agreement and Abell’s right to exercise is perpetual.

	The Abell Option represents a fixed obligation that is to be settled through the issuance of a variable number of shares of the Company’s common stock. Consistent with the provisions of ASC Topic 480, the Company has concluded that the Abell Option should be accounted for as a liability and should be recorded as the conditions necessary to trigger the holders rights to exercise are considered by management to be probable of occurring as of March 31, 2014. The Company is required to record the Abell Option at its estimated fair value at the end of each reporting period. The Company recorded the grant date fair value as a component of general and administrative expenses. Changes in the estimated fair value of the Abell Option will be recorded in the unaudited condensed consolidated statements of operations as a component of Gain (Loss) on Financial Instruments.

	As of March 31, 2014, the estimated value of the Abell Option is $6,074,770 which the Company has recorded as a liability. The Company has classified the carrying value of the Abell Option in Financial instruments in the accompanying unaudited condensed consolidated balance sheet. The Company has recorded a gain of $1,317,758 and $0 for the three months ended March 31, 2014 and 2013 respectively, representing the change in the fair value of the Abell Option. The initial value assigned to the Abell Option of $5,954,545 was recorded as a component of General & Administrative expense in the accompanying unaudited condensed consolidated financial statements for the three months ended March 31, 2013.

	Derivative Financial Instruments

	The Company may enter into transactions that represent free-standing or embedded derivative financial instruments as those terms are defined in ASC Topic 815 Derivatives and Hedging (“Topic 815”). The Company records the estimated fair value of derivative financial instruments in its consolidated balance sheets and records changes in the estimated fair value of derivative financial instruments as income or expense in its unaudited condensed consolidated statements of operations.

	Round C Warrants

	From October 2012 through December 2013 and then again from January 2014 through March 31, 2014, the Company issued warrants to certain investors in the common stock of the Company (the “Round C Warrants”). Round C Warrants to acquire 339,966 shares of common stock were issued through December 2013 and Round C Warrants to acquire 130,389 shares of common stock were issued during the three months ended March 31, 2014. The Round C Warrants have an exercise price of $6.05, a contractual term of 5 years and were fully vested upon issuance.

	The terms of the Round C Warrants provide for "down-round" anti-dilution adjustments in certain situations whereby the Company sells or issues (a) stock at a price per share less than the exercise price of the Round C Warrants or (b) equity linked financial instruments with an exercise price less than the exercise price of the Round C Warrants. Consistent with the provisions of ASC Topic 815-40, the Round C Warrants are classified as derivative financial instruments. The Company is required to record the estimated fair value of derivative financial instruments at the end of each reporting period, with changes in the estimated fair value of such derivatives recorded in the unaudited condensed consolidated statements of operations as a component of Gain (Loss) on Financial Instruments.

	As of March 31, 2014 and December 31, 2013, the estimated fair value of the liability associated with the Round C Warrants was $1,998,481 and $1,796,427, respectively, and is included in Financial Instruments in the accompanying condensed consolidated balance sheets. The Company has recorded a gain of $375,296 and $44,617 representing the change in the fair value of the Round C Warrants for the three months ended March 31, 2014 and 2013 respectively.

	2012 Bridge Loan

	Between April 2012 and October 2012, the Company entered into transactions with various investors which resulted in the Company raising $1,019,000 from the issuance of unsecured notes payable (collectively the “Bridge Loan”). The Bridge Loan has no contractual maturity date, and is repayable only in the event that the Company closes on a future round of equity financing which results in gross proceeds of at least $20 million. If the Company fails to raise sufficient additional capital, there is no obligation to pay interest or repay any amount borrowed under the Bridge Loan. Should the Company be successful in raising sufficient equity capital, the Company must repay an amount to the investors equal to 2 times the amount originally raised.

	The Company has classified the Bridge Loan as a derivative financial instrument, as it meets three qualifying criteria of ASC Topic 815 Derivatives and Hedging (“Topic 815”) including the contractual terms whereby the Company can be required to settle its obligation under the Bridge Loan by transferring cash to investors if and only when sufficient additional capital is raised. As of March 31, 2014, and December 31, 2013, the estimated fair value of the liability associated with the Bridge Loan was $720,000 and $990,000 respectively, which has been recorded and included in financial instruments in the accompanying condensed consolidated balance sheets.

	The change in the carrying value of the Bridge Loan includes a reduction of $270,000 representing the carrying value of the liability, as referenced in Note 9, related to those investors on the date of conversion. In April 2013, the board of directors authorized the Company to offer the investors in the 2012 Bridge Loan, the option to convert the amount otherwise due and payable to them in the event of a successful qualified offering, or $2,038,000, into common stock of the Company, at a per share price equal to that provided in the Round C common stock offering, or $5.50 per share plus 30% warrant coverage. In order to accommodate all Bridge Loan holders, the total dollar value of common stock issuable in the Round C offering was increased from $11 million to $13 million.

	During 2013, certain investors in the Bridge Loan elected to convert their rights to receive cash under the Bridge Loan into shares of common stock and common stock warrants. The accounts for these investors were increased to 2 times the amount originally invested creating a loss on financial instruments as of December 31, 2013 of $93,800. As a result, the Company issued 170,540 shares of common stock to certain holders of the Bridge Loan that had elected to convert their rights into common stock of the Company and an additional 4,787 Adjustment Shares as discussed in Note 10 of these unaudited condensed consolidated financial statements. The Company also issued additional Round C Warrants exercisable into 51,159 shares of common stock of the Company, with an exercise price of $6.05 per share.

	During the three months ended March 31, 2014, certain investors in the Bridge Loan elected to convert their rights to receive cash under the Bridge Loan into shares of common stock and common stock warrants. The accounts for these investors were increased to 2 times the amount originally invested creating a loss on financial instruments as of March 31, 2014 of $30,000. As a result, the Company issued 54,545 shares of common stock to certain holders of the Bridge Loan that had elected to convert their rights into common stock of the Company and an additional 1,530 Adjustment Shares as discussed in Note 10 of these unaudited condensed consolidated financial statements. The Company also issued additional Round C Warrants exercisable into 16,363 shares of common stock of the Company, with an exercise price of $6.05 per share.

	The Company has recorded a loss of $30,000 and $305,700 representing the change in the fair market carrying value of the Bridge Loan for the three months ended March 31, 2014 and 2013 respectively. This loss has been classified in Gain (Loss) on Financial Instruments in the accompanying unaudited condensed consolidated statements of operations.

Earnings Per Share, Policy [Policy Text Block]	'
	Net Loss Per Share

	Basic loss per share is determined by dividing loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted loss per share is computed by dividing the loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company's outstanding stock warrants, unvested restricted stock and the if-converted method is used to determine the dilutive effect of convertible preferred stock and convertible debt. The following common stock equivalents were excluded in the calculation of diluted loss per share because their effect would be anti-dilutive:

	Three months ended March 31,	2014		2013

	Stock Option Pool		77,000		-
	Abell Investment Option		934,579		1,136,364
	Convertible debt		76,923		91,324
	Restricted stock awards		134,278		119,734
	Warrants		3,575,948		2,780,906

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	3 Months Ended
Summary of Significant Accounting Policies (Tables)	Mar. 31, 2014
Accounting Policies [Abstract]	'
Schedule of Property Plant and Equipment Estimated Useful Life [Table Text Block]	'
	Property and equipment are recorded at cost and are depreciated or amortized over their estimated useful lives using the straight-line method. Estimated useful lives are as follows:


	Machinery and equipment	3 – 5 years
	Automobile	3 – 5 years
	Furniture and fixtures	5 years
	Computers and software	3 years

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	'
	The following common stock equivalents were excluded in the calculation of diluted loss per share because their effect would be anti-dilutive:

	Three months ended March 31,	2014		2013

	Stock Option Pool		77,000		-
	Abell Investment Option		934,579		1,136,364
	Convertible debt		76,923		91,324
	Restricted stock awards		134,278		119,734
	Warrants		3,575,948		2,780,906

Property_and_Equipment_Tables

Property and Equipment (Tables)	3 Months Ended
Property and Equipment (Tables)	Mar. 31, 2014
Property, Plant and Equipment, Net [Abstract]	'
Property, Plant and Equipment [Table Text Block]	'
	Property and equipment consisted of the following:

	Period ended	March 31, 2014		December 31, 2013

	Machinery and equipment	$	904,631	$	903,964
	Furniture and fixtures		35,690		35,690
	Computers and software		1,929		1,929
			942,250		941,583

	Less accumulated depreciation		-752,297		-742,793

		$	189,953	$	198,790

Intangible_Assets_Tables

Intangible Assets (Tables)	3 Months Ended
Intangible Assets (Tables)	Mar. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Finite-Lived Intangible Assets [Table Text Block]	'
	Intangible assets by major asset class were as follows at March 31, 2014:

		Gross Carrying		Accumulated		Net Carrying
		Amount		Amortization		Amount

	Intellectual Property	$	84,481,856	$	23,467,070	$	61,014,786
	Other Intangible Assets		121,944		86,988		34,956

		$	84,603,800	$	23,554,058	$	61,049,742

	Intangible assets by major asset class were as follows at December 31, 2013:

		Gross Carrying		Accumulated		Net Carrying
		Amount		Amortization		Amount

	Intellectual Property	$	84,481,856	$	21,792,439	$	62,689,417
	Other Intangible Assets		121,944		85,802		36,142

		$	84,603,800	$	21,878,241	$	62,725,559

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	'
	The estimated future amortization relating to all intangible assets that are recorded in the consolidated balance sheets as of March 31, 2014 is as follows:

	Years ending December 31,

	2014	$	5,022,713
	2015		6,698,530
	2016		6,698,530
	2017		6,698,530
	2018		6,698,530
	Thereafter		29,232,909
		$	61,049,742

Notes_Payable_Tables

Notes Payable (Tables)	3 Months Ended
Notes Payable (Tables)	Mar. 31, 2014
Notes Payable [Abstract]	'
Schedule of Short-term Debt [Table Text Block]	'
	Notes payable are as follows:

		March 31, 2014		December 31, 2013

	Organon Obligation	$	3,500,000	$	3,500,000
	Abell Loan		903,803		1,331,217

		$	4,403,803	$	4,831,217

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	3 Months Ended
Fair Value Measurements (Tables)	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]	'
	The Company’s financial instruments measured on a recurring basis using fair value estimates are as follows:

				March 31, 2014
	Description	Total		Level 1			Level 2		Level 3

	Abell Warrants	$	1,376,066	$	-		$	-	$	1,376,066
	Round C Warrants		1,998,481		-			-		1,998,481
	Bridge Loan		720,000		-			-		720,000
	Abell Investment Option		6,074,770		-			-		6,074,770

		$	10,169,317	$	-		$	-	$	10,169,317

				December 31, 2013
	Description	Total		Level 1			Level 2		Level 3

	Abell Warrants	$	1,615,835	$	-		$	-	$	1,615,835
	Round C Warrants		1,796,427		-			-		1,796,427
	Bridge Loan		990,000		-			-		990,000
	Abell Investment Option		7,392,528		-			-		7,392,528

		$	11,794,790	$	-		$	-	$	11,794,790

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	'
	The following is a reconciliation of the fair value measurements from December 31, 2013 to March 31, 2014.

		Abell		Round C			Bridge		Abell
		Warrants		Warrants			Loan		Option

	Balance, December 31, 2013	$	1,615,835	$	1,796,427		$	990,000	$	7,392,528
	Issuance of securities		37,529		577,350			-300,000		-
	Fair value change included in earnings		-277,298		-375,296			30,000		-1,317,758

	Balance, March 31, 2014	$	1,376,066	$	1,998,481		$	720,000	$	6,074,770

	The following is a reconciliation of the fair value measurements from December 31, 2012 to March 31, 2013.

		Abell		Round C			Bridge		Abell
		Warrants		Warrants			Loan		Option

	Balance, December 31, 2012	$	831,806	$	230,349		$	1,528,500	$	-
	Issuance of securities		275,813		169,024			-		5,954,545
	Fair value change included in earnings		-123,001		-44,617			305,700

	Balance, March 31, 2013	$	984,618	$	354,756		$	1,834,200	$	5,954,545

Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	'
	Quantitative information as of March 31, 2014 with respect to financial instruments measured and carried at fair value on a recurring basis with the use of significant unobservable inputs (Level 3) are as follows:

	Level 3 - Significant Unobservable Inputs

				Principal Valuation		Unobservable		Range
	Description	Fair Value		Techniques		Inputs		(Weighted Average)

	Abell Warrants	$	1,376,066	Black -Scholes		Strike price Equity volatility		N/A

	Round C Warrants	$	1,998,481	Black -Scholes		Strike price Equity volatility		N/A

	Bridge Loan	$	720,000	Present Value		Timing and amount of future cash flows		N/A

	Abell Investment Option	$	6,074,770	Black -Scholes		Strike price Equity volatility		N/A

Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]	'
	The following assumptions were used:

			Abell Warrants						Round C Warrants
	Three months ended March 31,		2014			2013			2014		2013

	Volatility		85%			80%			85%		90%
	Exercise price		$4.55			$4.68			$5.88		$6.05
	Stock price at March 31		$6.50			$5.42			$6.50		$5.42
	Risk free interest rate		2.66% - 2.77%			1.58% - 1.83%			1.12% - 1.73%		0.66- 0.73%
	Dividend yield		0%			0%			0%		0%
	Expected life		10			10			3.7 -5.0		4.6 – 5.0

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	3 Months Ended
Stock-Based Compensation (Tables)	Mar. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]	'
	The weighted average fair values for the awards below are based on the fair value at the grant date of the respective awards, which is equal to the value of the Company’s common stock on such date.

		2014						2013
	Three months ended March 31,	Shares			Weighted			Shares		Weighted
					Average					Average
					Fair Value					Fair Value

	Balance, January 1		134,278		$	3.91			119,734	$	3.42
	Granted		-			-			-		-
	Vested		-			-			-		-
	Forfeitures		-			-			-		-

	Balance, March 31		134,278		$	3.91			119,734	$	3.42

Schedule Of Fair Value Assumptions [Table Text Block]	'
	The Company uses the Black-Scholes option pricing model to calculate the fair value of options. The significant assumptions used in this model include:

	Annual Dividend	-
	Expected life (in years)	6.25 – 10.00
	Risk free interest rate	1.35% - 2.17%
	Expected volatility	80%

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	'
	The following table summarizes the Stock Option pool activity for the three months ended March 31, 2014. No Stock Options were granted as of March 31, 2013.

		Shares			Weighted Average				Weighted Average
		Shares			Exercise Price				Remaining Life
	Balance, January 1, 2014		77,000		$	7			3.45
	Granted		-			-			-
	Forfeited		-			-			-
	Balance, March 31. 2014		77,000		$	7			3.2

Schedule Of Share Based Compensation Arrangements By Share Based Payment Award Warrants [Table Text Block]	'
	The following table summarizes the stock purchase warrant activity for the three months ended March 31, 2014 and 2013.

		2014						2013
		Shares			Weighted			Shares		Weighted
					Average Fair					Average Fair
					Value					Value

	Balance, January 1		785,575		$	1.48			785,575	$	1.48
	Granted		-			-			-		-

	Balance, March 31		785,575		$	1.48			785,575	$	1.48

Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	'
	The following table summarizes information on warrants outstanding as of March 31, 2014:

	Exercise price	Shares		Weighted Average			Weighted Average
	Exercise price	Shares		Remaining Life			Exercise Price

	$1.00	705,575			0.8		$	1
	$5.50	80,000			3.49		$	5.5

	Total	785,575

Schedule Of Warrants Activity [Table Text Block]	'
	The following table summarizes the warrant activity for the three months ended March 31, 2014 and is inclusive of the Abell Warrants, the Round C Warrants, the Stock Purchase Warrants and represents the total outstanding warrants.

		Shares			Weighted Average			Weighted Average
		Shares			Exercise Price			Remaining Life
	Outstanding at January 1, 2014		3,310,378		$	2.2			2.95
	Granted		265,570		$	5.35			7.41
	Exercised		-			-			-
	Expired		-			-			-
	Outstanding at March 31, 2014		3,575,948		$	2.44			3.12

Summary of Outstanding Warrants by year of Expiration [Table Text Block]	'
	The following table summarizes the outstanding warrants by year of expiration:

		Shares
	2014		1,151,690
	2015		1,201,475
	2016		-
	2017		139,439
	2018		280,527
	Thereafter		802,817
	Total		3,575,948

Going_Concern_Details_Textual

Going Concern (Details Textual) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Retained Earnings (Accumulated Deficit), Total	($104,957,438)	($103,279,321)
Working Capital	$19,700,000	'

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details)	3 Months Ended
Summary of Significant Accounting Policies (Details)	Mar. 31, 2014
Furniture and Fixtures [Member]	'
Property, Plant and Equipment [Line Items]	'
Property, Plant and Equipment, Useful Life	'5 years
Computers and software [Member]	'
Property, Plant and Equipment [Line Items]	'
Property, Plant and Equipment, Useful Life	'3 years
Minimum [Member] \| Machinery and Equipment [Member]	'
Property, Plant and Equipment [Line Items]	'
Property, Plant and Equipment, Useful Life	'3 years
Minimum [Member] \| Automobiles [Member]	'
Property, Plant and Equipment [Line Items]	'
Property, Plant and Equipment, Useful Life	'3 years
Maximum [Member] \| Machinery and Equipment [Member]	'
Property, Plant and Equipment [Line Items]	'
Property, Plant and Equipment, Useful Life	'5 years
Maximum [Member] \| Automobiles [Member]	'
Property, Plant and Equipment [Line Items]	'
Property, Plant and Equipment, Useful Life	'5 years

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Details 1)	3 Months Ended
Summary of Significant Accounting Policies (Details 1)	Mar. 31, 2014	Mar. 31, 2013
Stock Option Pool [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	77,000	0
Abell Investment Option [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	934,579	1,136,364
Convertible debt [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	76,923	91,324
Restricted stock awards [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	134,278	119,734
Warrants [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3,575,948	2,780,906

Summary_of_Significant_Account5

Summary of Significant Accounting Policies (Details Textual)

1 Months Ended

3 Months Ended

7 Months Ended

12 Months Ended

1 Months Ended

3 Months Ended

7 Months Ended

12 Months Ended

1 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

1 Months Ended

3 Months Ended

Jan. 31, 2013

Feb. 28, 2012

Mar. 31, 2014

Mar. 31, 2013

Oct. 31, 2012

Dec. 31, 2013

Aug. 31, 2012

Apr. 30, 2013

Mar. 31, 2014

Oct. 31, 2012

Dec. 31, 2013

Jan. 16, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Dec. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Dec. 31, 2013

Apr. 30, 2013

Mar. 31, 2014

Dec. 31, 2013

Nov. 30, 2013

Oct. 31, 2013

Sep. 30, 2013

Aug. 31, 2013

Feb. 28, 2012

Mar. 31, 2014

Jul. 31, 2014

Jul. 01, 2014

Jun. 01, 2014

1-May-14

Apr. 01, 2014

Mar. 01, 2014

Feb. 01, 2014

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

USD ($)

EUR (€)

USD ($)

Bridge Loan [Member]

Abell Investment Option [Member]

Abell Option [Member]

Abell Warrant [Member]

Round C Warrant [Member]

July Amendment [Member]

February Amendment [Member]

Vaccinogen BV [Member]

Patents [Member]

USD ($)

Bridge Loan [Member]

USD ($)

Malpractice Insurance, Annual Coverage Limit

$250,000

€ 100

Finite-Lived Intangible Asset, Useful Life

'12 years 3 months 18 days

Assets, Total

61,681,323

63,257,511

252,000

263,000

Retained Earnings (Accumulated Deficit), Total

-104,957,438

-103,279,321

253,000

314,000

Income (Loss) from Subsidiaries, Net of Tax, Total

349,000

387,000

Debt Instrument, Convertible, Terms of Conversion Feature

'The number of shares issuable pursuant to the Abell Warrants was originally determined based upon a fixed amount of $500,000 divided by 85% of the per share price of stock sold in the next qualifying round of venture capital financing (defined as a round that raised at least $20 million).

'In connection with February 2012 amendment to the borrowing arrangement, the fixed amount used to determine the ultimate number of shares into which the Abell Warrants are exercisable was increased to $800,000.

Warrants Exercisable

1,100,000

800,000

Proceeds From Venture Capital Financing

35,000,000

Warrants Contractual Term

'10 years

'5 years

Warrants Not Settleable in Cash, Fair Value Disclosure

794,000

1,376,066

1,615,835

1,998,481

1,796,427

Fair Value, Option, Changes in Fair Value, Gain (Loss)

1,317,758

239,769

123,001

375,296

44,617

Contingent Warrants Additional Share Issuable

100,000

80,000

60,000

40,000

20,000

Contingent Warrants Exercisable Price Details

'that is it will depend upon a value equal to 85% of the lowest price paid a qualified future raise of equity capital.

Interest Expense, Total

852,885

65,230

794,000

Financial Liabilities Fair Value Disclosure, Total

10,169,317

11,794,790

6,074,770

Selling, General and Administrative Expense, Total

5,954,545

Debt Instrument, Convertible, Number of Equity Instruments

130,389

339,966

16,363

51,159

Class of Warrant or Right, Exercise Price of Warrants or Rights

6.05

Proceeds from Unsecured Notes Payable

1,019,000

Loans Payable, Fair Value Disclosure

720,000

990,000

Reducton Of Liabilities

270,000

Debt Instrument, Convertible, Carrying Amount of Equity Component

20,000,000

2,038,000

Debt Instrument, Convertible, Conversion Price

$5.50

Warrant Coverage

30.00%

Common Stock Issuable Value

11,000,000

Derivative, Loss on Derivative

30,000

93,800

Common Stock, Shares, Issued

32,015,480

31,568,629

200,000,000

54,545

170,540

Increase or Decrease In Bridge Loan

30,000

305,700

Proceeds from Issuance or Sale of Equity, Total

999,866

971,836

20,000,000

Common Stock Issuable Value Increased

13,000,000

Contingent Warrants Maximum Share Issuable

120,000

60,000

360,000

Additional Common Stock Shares Issued

972,000

1,530

4,787

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross value

500,000

5,000,000

275,813

Unrecognized Tax Benefits, Interest on Income Taxes Accrued

130,000

Deferred Tax Assets, Valuation Allowance

19,000,000

18,000,000

Repayments of Debt

$300,000

Agreements_with_Intracel_Detai

Agreements with Intracel (Details Textual) (USD $)

Mar. 31, 2014

Dec. 31, 2013

Aug. 31, 2012

Mar. 31, 2014

Dec. 31, 2010

Jun. 30, 2010

Oct. 31, 2007

Mar. 31, 2014

Jun. 24, 2010

Oct. 31, 2007

Mar. 31, 2014

Oct. 31, 2007

Series B Preferred Stock [Member]

Assets Transfer Agreement [Member]

License Agreement Terms [Member]

Trade Payable [Member]

Intracel Ltd [Member]

Stock Holder One [Member]

Series B Preferred Stock [Member]

Common Stock And Series AA Preferred Stock [Member]

Officers and Directors [Member]

Series B Preferred Stock [Member]

Agreement [Line Items]

Equity Method Investment, Ownership Percentage

50.00%

10.00%

20.00%

10.00%

42.00%

31.00%

20.00%

10.00%

Liabilities Assumed

$4,000,000

Settlement Liabilities, Current

450,000

Common Stock, Shares, Issued

32,015,480

31,568,629

200,000,000

1,506,750

Common Stock, Value, Issued

3,202

3,157

984,000

Equity, Fair Value Disclosure, Total

4,450,000

Preferred Stock, Shares Issued

10,973,612

3,452,766

Preferred Stock, Value, Issued

$63,100,000

$16,800,000

Contingent_Equity_Lines_of_Cre1

Contingent Equity Lines of Credit (Details Textual) (USD $)	3 Months Ended		12 Months Ended		1 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013	Mar. 31, 2014	Jul. 18, 2012	Jun. 18, 2012
			Kodiak [Member]	Kodiak [Member]	Kodiak [Member]	Kodiak [Member]
				Subsequent Investment Agreement [Member]	Initial Investment Agreement [Member]	Initial Investment Agreement [Member]
					Subsequent Open Period [Member]	Initial Open Period [Member]
Line of Credit Facility [Line Items]	'	'	'	'	'	'
Issuance Of Common Stock Aggregate Purchase Price	'	'	'	'	$25,000,000	'
Aggregate Purchase Price Of Common Stock	'	'	'	26,000,000	'	1,000,000
Debt Issuance Cost	'	'	25,000	'	'	'
Stock Issued During Period, Shares, New Issues	'	'	236,364	'	'	'
Stock Issued During Period, Value, New Issues	'	'	1,300,000	'	'	'
General and Administrative Expense, Total	$707,927	$6,929,760	$1,300,000	'	'	'

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]	'	'
Property Plant And Equipment Gross	$942,250	$941,583
Less accumulated depreciation	-752,297	-742,793
Property, Plant and Equipment, Net ,Total	189,953	198,790
Machinery and equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property Plant And Equipment Gross	904,631	903,964
Furniture and fixtures [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property Plant And Equipment Gross	35,690	35,690
Computers and software [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property Plant And Equipment Gross	$1,929	$1,929

Property_and_Equipment_Details1

Property and Equipment (Details Textual) (USD $)	3 Months Ended
Property and Equipment (Details Textual) (USD $)	Mar. 31, 2014	Mar. 31, 2013
Property, Plant and Equipment [Line Items]	'	'
Depreciation	$9,504	$7,356

Intangible_Assets_Details

Intangible Assets (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]	'	'
GrossCarrying Amount	$84,603,800	$84,603,800
Accumulated Amortization	23,554,058	21,878,241
Intangible assets, net	61,049,742	62,725,559
Intellectual Property [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
GrossCarrying Amount	84,481,856	84,481,856
Accumulated Amortization	23,467,070	21,792,439
Intangible assets, net	61,014,786	62,689,417
Other Intangible Assets [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
GrossCarrying Amount	121,944	121,944
Accumulated Amortization	86,988	85,802
Intangible assets, net	$34,956	$36,142

Intangible_Assets_Details_1

Intangible Assets (Details 1) (USD $)	Mar. 31, 2014
Finite-Lived Intangible Assets [Line Items]	'
2014	$5,022,713
2015	6,698,530
2016	6,698,530
2017	6,698,530
2018	6,698,530
Thereafter	29,232,909
Finite-Lived Intangible Assets, Net, Total	$61,049,742

Intangible_Assets_Details_Text

Intangible Assets (Details Textual) (USD $)	3 Months Ended
Intangible Assets (Details Textual) (USD $)	Mar. 31, 2014	Mar. 31, 2013
Finite-Lived Intangible Assets [Line Items]	'	'
Intellectual Property Purchase Price Description	'The total purchase price for the Intellectual Property was ultimately determined based upon the estimated fair value of the Series B preferred stock representing a 50% stock ownership in the Company, the value of cash payments made of $450,000 and, obligations of Intracel assumed of $4 million.	'
Amortization of Intangible Assets	$1,675,816	$1,675,817
Finite-Lived Intangible Assets, Remaining Amortization Period	'12 years 7 months 6 days	'

Notes_Payable_Details

Notes Payable (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Short-term Debt [Line Items]	'	'
Notes Payable, Current	$4,403,803	$4,831,217
Organon Obligation [Member]	'	'
Short-term Debt [Line Items]	'	'
Notes Payable, Current	3,500,000	3,500,000
Abell Loan [Member]	'	'
Short-term Debt [Line Items]	'	'
Notes Payable, Current	$903,803	$1,331,217

Notes_Payable_Details_Textual

Notes Payable (Details Textual) (USD $)

0 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

Feb. 16, 2012

Mar. 31, 2014

Mar. 31, 2013

Jan. 31, 2014

Mar. 31, 2014

Jul. 31, 2014

Jul. 01, 2014

Jun. 01, 2014

1-May-14

Apr. 01, 2014

Mar. 01, 2014

Feb. 01, 2014

Jan. 31, 2014

Feb. 01, 2014

Oct. 31, 2007

Sep. 30, 2007

Mar. 31, 2014

Mar. 31, 2013

Oct. 31, 2008

Oct. 31, 2007

Mar. 31, 2014

Mar. 31, 2013

Dec. 31, 2013

Oct. 26, 2011

Feb. 16, 2012

February Amendment [Member]

Seventh Amended and Restated Promissory Note [Member]

Organon Obligation [Member]

Abell Loan [Member]

First Installment [Member]

Working Capital Loan [Member]

Additional Loan [Member]

Short-term Debt [Line Items]

Long-term Debt, Gross

$3,500,000

$4,000,000

$1,500,000

$300,000

Debt Instrument, Periodic Payment, Principal

500,000

Debt Instrument, Increase, Accrued Interest

500,000

Debt Instrument, Periodic Payment, Interest

128,000

500,000

Debt Instrument, Annual Principal Payment

1,000,000

Debt Instrument, Interest Rate, Stated Percentage

4.00%

8.00%

Interest Paid, Total

23,500

38,550

35,000

22,000

36,000

Debt Instrument, Increase (Decrease), Net, Total

1,800,000

Class Of Warrants or Rights Issued

300,000

Debt Instrument Interest Rate Increases, Due To Default

10.00%

Warrants Exercisable Details

'The number of shares into which the Abell Warrants are exercisable was revised with each amendment to the Abell Loan and is ultimately equal $1.1 million divided by 85% of the purchase price per share of stock sold in the Companys next venture capital financing resulting in proceeds of not less than $35.0 million

Debt Instrument, Fair Value Disclosure

275,813

Contingent Warrants Maximum Share Issuable

60,000

360,000

Proceeds from Issuance or Sale of Equity, Total

999,866

971,836

5,693,135

Debt Instrument, Face Amount

1,038,957

Debt Instrument, Maturity Date

31-Jul-14

Percentage Of Debt Equity Issuance

25.00%

Interest Expense, Debt, Excluding Amortization

1,700,000

Debt Instrument, Maturity Date, Description

'Effective January 1, 2014 the maturity date was extended to January 31, 2014. No costs or expenses were incurred by the Company in connection with the January amendment

Interest Expense, Total

$852,885

$65,230

$794,000

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Liabilities, Fair Value Disclosure, Recurring	$10,169,317	$11,794,790
Fair Value, Inputs, Level 1 [Member]	'	'
Liabilities, Fair Value Disclosure, Recurring	0	0
Fair Value, Inputs, Level 2 [Member]	'	'
Liabilities, Fair Value Disclosure, Recurring	0	0
Fair Value, Inputs, Level 3 [Member]	'	'
Liabilities, Fair Value Disclosure, Recurring	10,169,317	11,794,790
Abell Option [Member]	'	'
Liabilities, Fair Value Disclosure, Recurring	1,376,066	1,615,835
Abell Option [Member] \| Fair Value, Inputs, Level 1 [Member]	'	'
Liabilities, Fair Value Disclosure, Recurring	0	0
Abell Option [Member] \| Fair Value, Inputs, Level 2 [Member]	'	'
Liabilities, Fair Value Disclosure, Recurring	0	0
Abell Option [Member] \| Fair Value, Inputs, Level 3 [Member]	'	'
Liabilities, Fair Value Disclosure, Recurring	1,376,066	1,615,835
Round C Warrants [Member]	'	'
Liabilities, Fair Value Disclosure, Recurring	1,998,481	1,796,427
Round C Warrants [Member] \| Fair Value, Inputs, Level 1 [Member]	'	'
Liabilities, Fair Value Disclosure, Recurring	0	0
Round C Warrants [Member] \| Fair Value, Inputs, Level 2 [Member]	'	'
Liabilities, Fair Value Disclosure, Recurring	0	0
Round C Warrants [Member] \| Fair Value, Inputs, Level 3 [Member]	'	'
Liabilities, Fair Value Disclosure, Recurring	1,998,481	1,796,427
Bridge Loan [Member]	'	'
Liabilities, Fair Value Disclosure, Recurring	720,000	990,000
Bridge Loan [Member] \| Fair Value, Inputs, Level 1 [Member]	'	'
Liabilities, Fair Value Disclosure, Recurring	0	0
Bridge Loan [Member] \| Fair Value, Inputs, Level 2 [Member]	'	'
Liabilities, Fair Value Disclosure, Recurring	0	0
Bridge Loan [Member] \| Fair Value, Inputs, Level 3 [Member]	'	'
Liabilities, Fair Value Disclosure, Recurring	720,000	990,000
Abell Warrant [Member]	'	'
Liabilities, Fair Value Disclosure, Recurring	6,074,770	7,392,528
Abell Warrant [Member] \| Fair Value, Inputs, Level 1 [Member]	'	'
Liabilities, Fair Value Disclosure, Recurring	0	0
Abell Warrant [Member] \| Fair Value, Inputs, Level 2 [Member]	'	'
Liabilities, Fair Value Disclosure, Recurring	0	0
Abell Warrant [Member] \| Fair Value, Inputs, Level 3 [Member]	'	'
Liabilities, Fair Value Disclosure, Recurring	$6,074,770	$7,392,528

Fair_Value_Measurements_Detail1

Fair Value Measurements (Details 1) (USD $)	3 Months Ended
Fair Value Measurements (Details 1) (USD $)	Mar. 31, 2014	Mar. 31, 2013
Abell Warrants [Member]	'	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Beginning Balance	$1,615,835	$831,806
Issuance of securities	37,529	275,813
Fair value change included in earnings	-277,298	-123,001
Ending Balance	1,376,066	984,618
Round C Warrants [Member]	'	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Beginning Balance	1,796,427	230,349
Issuance of securities	577,350	169,024
Fair value change included in earnings	-375,296	-44,617
Ending Balance	1,998,481	354,756
Bridge Loan [Member]	'	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Beginning Balance	990,000	1,528,500
Issuance of securities	-300,000	0
Fair value change included in earnings	30,000	305,700
Ending Balance	720,000	1,834,200
Abell Option [Member]	'	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Beginning Balance	7,392,528	0
Issuance of securities	0	5,954,545
Fair value change included in earnings	-1,317,758	'
Ending Balance	$6,074,770	$5,954,545

Fair_Value_Measurements_Detail2

Fair Value Measurements (Details 2) (USD $)	3 Months Ended
Fair Value Measurements (Details 2) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Liabilities, Fair Value Disclosure, Recurring	$10,169,317	$11,794,790
Round C Warrants [Member]	'	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Liabilities, Fair Value Disclosure, Recurring	1,998,481	1,796,427
Bridge Loan [Member]	'	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Liabilities, Fair Value Disclosure, Recurring	720,000	990,000
Abell Option [Member]	'	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Liabilities, Fair Value Disclosure, Recurring	1,376,066	1,615,835
Fair Value, Inputs, Level 3 [Member]	'	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Liabilities, Fair Value Disclosure, Recurring	10,169,317	11,794,790
Fair Value, Inputs, Level 3 [Member] \| Abell Warrants [Member]	'	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Liabilities, Fair Value Disclosure, Recurring	1,376,066	'
Fair Value Measurements, Valuation Techniques	'Black -Scholes	'
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings, Description	'Strike price Equity volatility	'
Fair Value, Inputs, Level 3 [Member] \| Round C Warrants [Member]	'	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Liabilities, Fair Value Disclosure, Recurring	1,998,481	1,796,427
Fair Value Measurements, Valuation Techniques	'Black -Scholes	'
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings, Description	'Strike price Equity volatility	'
Fair Value, Inputs, Level 3 [Member] \| Bridge Loan [Member]	'	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Liabilities, Fair Value Disclosure, Recurring	720,000	990,000
Fair Value Measurements, Valuation Techniques	'Present Value	'
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings, Description	'Timing and amount of future cash flows	'
Fair Value, Inputs, Level 3 [Member] \| Abell Option [Member]	'	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Liabilities, Fair Value Disclosure, Recurring	$1,376,066	$1,615,835
Fair Value Measurements, Valuation Techniques	'Black -Scholes	'
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings, Description	'Strike price Equity volatility	'

Fair_Value_Measurements_Detail3

Fair Value Measurements (Details 3) (USD $)

Oct. 31, 2012

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Abell Warrants [Member]

Round C Warrants [Member]

Maximum [Member]

Minimum [Member]

Abell Warrants [Member]

Round C Warrants [Member]

Abell Warrants [Member]

Round C Warrants [Member]

Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]

Volatility

85.00%

80.00%

85.00%

90.00%

Exercise price

$4.55

$4.68

$5.88

$6.05

Stock price

$5.35

$6.50

$5.42

$6.50

$5.42

Risk free interest rate

2.77%

1.83%

1.73%

0.73%

2.66%

1.58%

1.12%

0.66%

Dividend yield

0.00%

Expected life (in years)

'10 years

'5 years

'3 years 8 months 12 days

'4 years 7 months 6 days

Fair_Value_Measurements_Detail4

Fair Value Measurements (Details Textual) (USD $)	3 Months Ended	12 Months Ended
In Millions, except Share data, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013	Jan. 16, 2013
Shares Issued, Price Per Share	$6.50	$7.91	$5.50
Discounted Share Price Per Share	'	'	$4.40
Investment Owned, Face Amount	'	'	$5
Yielded Number Of Shares	1,136,364	934,580	'
Expected Venture Capital Financing Price Per Share	$5.35	'	'

Redeemable_Preferred_Stock_and1

Redeemable Preferred Stock and Stockholders' Equity (Details Textual) (USD $)

3 Months Ended

7 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

Mar. 31, 2014

Oct. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Aug. 31, 2012

Jan. 01, 2011

Dec. 31, 2010

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Aug. 01, 2012

Oct. 24, 2011

Jan. 01, 2011

Dec. 31, 2010

Aug. 01, 2012

Jan. 01, 2011

Dec. 31, 2010

Placement Agent [Member]

Placement Agent Warrants [Member]

Kodiak [Member]

Bridge Loan 2013 [Member]

Round C Warrants [Member]

Round C Stock [Member]

Round C Stock And Round C Warrants [Member]

Series AA preferred Stock [Member]

Series B Preferred Stock [Member]

Bridge Loan 2013 [Member]

Common Stock, Shares Authorized

200,000,000

75,000,000

Common Stock, Par or Stated Value Per Share

$0.00

Preferred Stock, Shares Authorized

50,000,000

123,015

15,000,000

35,000,000

Preferred Stock, Par or Stated Value Per Share

$0.00

$9.08

$0.00

$9.08

$0.00

Conversion of Stock, Shares Issued

1,507,666

16,656,082

Common Stock, Shares, Issued

32,015,480

31,568,629

200,000,000

4,188,727

5,097,817

236,364

30,860

764,578

167,273

170,540

Redeemable Noncontrolling Interest, Equity, Common, Fair Value

$1,300,000

Additional Paid in Capital, Total

146,484,487

143,920,855

169,729

4,205,105

920,002

937,970

Stock Issued During Period, Shares, Conversion of Convertible Securities

229,368

9,258

51,159

50,181

Proceeds from Issuance of Common Stock

751,561

133,624

3,253,316

725,757

Proceeds From Issuance of Common Stock Warrants

926,581

36,105

23,038,000

28,030,000

186,409

194,245

Proceeds from Issuance of Preferred Stock and Preference Stock

1,100,000

Anti-Dilution Protection Description

'The Company filed a Form S-1 Registration Statement with the SEC, which became effective on October 31, 2013. The Effectiveness Date Market Price of Vaccinogen stock as of that date was $5.35. Pursuant to the protection provided to subscribers prior to October 31, 2013, 27,213 adjustment shares were issued. All subscriptions subsequent to the October 31, 2013 effective date through December 31, 2013 have been issued adjustment shares, totaling 31,811 and 12,207 adjustment shares issued for the three months ended March 31, 2014. All of the adjustment shares are included in the calculation of total shares issued or outstanding for the periods ended March 31, 2014 and December 31, 2013.

'if the market price of the Companys common stock on the effective date of the Companys first S-1 registration statement filed with the SEC (the Effectiveness Date Market Price) is less than $5.50 per share, then the Company will issue to each subscriber additional shares of common stock. The number of shares issued would equal the difference between a) the number of shares that would have been issued if the price per unit was equal to the greater of the Effectiveness Date Market Price or $5.00 and b) the number of shares originally issued to the subscriber

Payments of Stock Issuance Costs

14,000

Share Price

$5.35

Stock Issued During Period Shares Prior To Antidilution Protection

27,213

Stock Issued During Period Shares After Antidilution Protection

12,207

31,811

Stock Issued During Period Adjusted

21,465

4.787

Payments for Commissions

$14,542

$10,746

StockBased_Compensation_Detail

Stock-Based Compensation (Details) (USD $)	3 Months Ended
Stock-Based Compensation (Details) (USD $)	Mar. 31, 2014	Mar. 31, 2013
Options, Outstanding Shares	'	'
Balance, end of year	3,575,948	'
Restricted Stock [Member]	'	'
Options, Outstanding Shares	'	'
Balance, beginning of year	134,278	119,734
Granted	0	0
Vested	0	0
Forfeitures	0	0
Balance, end of year	134,278	119,734
Weighted Average Fair Value	'	'
Balance, beginning of year	$3.91	$3.42
Granted	$0	$0
Vested	$0	$0
Forfeitures	$0	$0
Balance, end of year	$3.91	$3.42

StockBased_Compensation_Detail1

Stock-Based Compensation (Details 1)	3 Months Ended
Stock-Based Compensation (Details 1)	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Expected volatility	80.00%
Annual Dividend	0.00%
Maximum [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Risk free interest rate	2.17%
Expected life (in years)	'10 years
Minimum [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Risk free interest rate	1.35%
Expected life (in years)	'6 years 3 months

StockBased_Compensation_Detail2

Stock-Based Compensation (Details 2) (USD $)	3 Months Ended	12 Months Ended
Stock-Based Compensation (Details 2) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Options, Outstanding Shares	'	'
Balance, end of year	3,575,948	'
Stock Option Pool [Member]	'	'
Options, Outstanding Shares	'	'
Balance, beginning of year	77,000	'
Granted	0	'
Forfeited	0	'
Balance, end of year	77,000	77,000
Weighted Average Exercise Price	'	'
Balance, beginning of year	$7	'
Granted	$0	'
Forfeited	$0	'
Balance, end of year	$7	$7
Weighted Average Remaining Life	'	'
Balance	'3 years 2 months 12 days	'3 years 5 months 12 days
Granted	'0 years	'
Forfeited	'0 years	'
Balance	'3 years 2 months 12 days	'3 years 5 months 12 days

StockBased_Compensation_Detail3

Stock-Based Compensation (Details 3) (USD $)	3 Months Ended
Stock-Based Compensation (Details 3) (USD $)	Mar. 31, 2014	Mar. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]	'	'
Balance, end of year	3,575,948	'
Warrant Activity [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]	'	'
Balance, beginning of year	785,575	785,575
Granted	0	0
Balance, end of year	785,575	785,575
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]	'	'
Balance, beginning of year	$1.48	$1.48
Granted	$0	$0
Balance, end of year	$1.48	$1.48

StockBased_Compensation_Detail4

Stock-Based Compensation (Details 4) (USD $)	3 Months Ended
Stock-Based Compensation (Details 4) (USD $)	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Warrants Outstanding, Shares	785,575
Exercise Price 1.00 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Warrants Outstanding, Shares	705,575
Warrants Outstanding, WeightedAverage remaining life	'9 months 18 days
Warrants Outstanding, WeightedAverage ExercisePrice	1
Exercise Price 5.50 [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Warrants Outstanding, Shares	80,000
Warrants Outstanding, WeightedAverage remaining life	'3 years 5 months 26 days
Warrants Outstanding, WeightedAverage ExercisePrice	5.5

StockBased_Compensation_Detail5

Stock-Based Compensation (Details 5) (USD $)	3 Months Ended	12 Months Ended
Stock-Based Compensation (Details 5) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Options, Outstanding Shares	'	'
Balance, end of year	3,575,948	'
Total Warrant Activity [Member]	'	'
Options, Outstanding Shares	'	'
Balance, beginning of year	3,310,378	'
Granted	265,570	'
Exercised	0	'
Expired	0	'
Balance, end of year	'	3,310,378
Weighted Average Exercise Price	'	'
Balance, beginning of year	$2.20	'
Granted	$5.35	'
Exercised	$0	'
Expired	$0	'
Balance, end of year	$2.44	$2.20
Weighted Average Remaining Life	'	'
Balance, beginning of year	'3 years 1 month 13 days	'2 years 11 months 12 days
Granted	'7 years 4 months 28 days	'
Exercised	'0 years	'
Expired	'0 years	'
Balance, end of year	'3 years 1 month 13 days	'2 years 11 months 12 days

StockBased_Compensation_Detail6

Stock-Based Compensation (Details 6)	3 Months Ended
Stock-Based Compensation (Details 6)	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Number of warrants outstanding expire	3,575,948
Two Thousand Fourteen Year [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Number of warrants outstanding expire	1,151,690
Two Thousand Fifteen Year [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Number of warrants outstanding expire	1,201,475
Two Thousand Sixteen Year [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Number of warrants outstanding expire	0
Two Thousand Seventeen Year [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Number of warrants outstanding expire	139,439
Two Thousand Eighteen Year [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Number of warrants outstanding expire	280,527
After Two Thousand Eighteen Year [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Number of warrants outstanding expire	802,817

StockBased_Compensation_Detail7

Stock-Based Compensation (Details Textual) (USD $)

3 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

Mar. 31, 2014

Mar. 31, 2013

Oct. 23, 2012

Mar. 31, 2014

Jul. 17, 2012

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2010

Mar. 31, 2014

Employee Stock Option [Member]

Vaccinogen [Member]

Warrant [Member]

Employees And Consultants [Member]

Maximum [Member]

Minimum [Member]

Restricted Stock [Member]

Warrant [Member]

2007 [Member]

2010 [Member]

Officer [Member]

Maximum [Member]

Minimum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

200,000

87,000

180,000

1,100,000

462,500

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

'7 years 1 month 13 days

'10 years

'4 years

'5 years

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total

$353,000

$524,000

$489,000

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition

'3 years 2 months 12 days

Bonafide Equity Capital

35,000,000

Issuance of Stock and Warrants for Services or Claims

785,575

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance

$5.50

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term

'7 years 6 months

'2 years 6 months

Stock Options Granted To Purchase Common Stock Shares

20,000

Share-based Compensation, Total

22,603

Share Based Compensation Arrangement By Share Based Payment Award Non vested Options Outstanding Number

134,278

General and Administrative Expense, Total

707,927

6,929,760

4,777

Research and Development Expense, Total

$2,020,128

$2,073,184

$17,826

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value

$5.45

$3.79

Commitments_and_Contingencies_

Commitments and Contingencies (Details Textual)	3 Months Ended				3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2011	Dec. 31, 2010	Mar. 31, 2014	Mar. 31, 2014
	USD ($)	USD ($)	EUR (€)	EUR (€)	Intracel [Member]	Organon [Member]
Operating Leases, Rent Expense	$40,591	$41,333	'	'	'	'
Operating Leases, Future Minimum Payments, Remainder of Fiscal Year	94,055	'	'	'	'	'
Operating Leases, Future Minimum Payments, Due in Two Years	20,968	'	'	'	'	'
Operating Leases, Future Minimum Payments Due, Total	115,023	'	'	'	'	'
Royalty Agreement Payment Terms	'	'	'	'	'Pursuant to the Agreement, the Company agreed to pay Intracel the following royalties on the Net Sales of Royalty Bearing Products (as defined): (i) 3% of net sales on the first $350.0 million of Net Sales of Colon Cancer Products occurring in the calendar year; (ii) 4% of net sales of Net Sales of Royalty Bearing Products occurring in the calendar year in excess of $350.0 million and up to and including $750.0 million and (iii) 5% of net sales of Net Sales of Royalty Bearing Products occurring in the calendar year in excess of $750.0 million.	'
Royalty Rate	'	'	'	'	'	10.00%
Royalty Rate Payment Due, There After	3.00%	'	'	'	'	'
Loss Contingency, Estimate of Possible Loss	150,000	'	'	'	'	'
Loss Contingency, Accrual, Current	75,000	'	'	'	'	'
Value Added Tax Payable	$90,000	'	€ 65,666	€ 65,666	'	'

Related_Party_Transactions_Det

Related Party Transactions (Details Textual) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Apr. 15, 2012	Dec. 31, 2013	Dec. 31, 2012	Feb. 14, 2012
Related Party Transactions (Details Textual) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Apr. 15, 2012	Executive Officer [Member]	Executive Officer [Member]	Board of Directors Chairman [Member]
Unsecured Debt, Current	'	'	$30,000	'	'	'
Minimum Shares Of Common Stock Issued Value	'	'	1,000,000	'	'	'
Due to Related Parties, Current	0	54,099	'	4,099	10,000	'
Due to Related Parties	'	70,000	'	'	'	169,729
Stock Issued During Period, Shares, New Issues	'	'	'	'	'	30,860
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	'	'	'	'	'	9,258
Loans and Leases Receivable, Related Parties	'	$20,000	'	'	'	'

Supplemental_Disclosure_of_Cas1

Supplemental Disclosure of Cash Flow Information (Details Textual) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013	Dec. 31, 2012
Interest Paid, Total	$23,500	$38,550	'	'
Additional Common Stock Shares Issued	'	972,000	'	'
Warrants Issued To Purchase Of Common Stock	112,663	'	'	'
Additional Paid In Capital Common Stock And Warrants	2,000,000	'	'	'
Additional Paid In Capital Common Stock And Warrants, Share	'	176,697	'	'
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights adjustment Shares	'	53,008	'	'
Proceeds from Issuance of Common Stock	'	'	751,561	133,624
Round C Warrants [Member]	'	'	'	'
Proceeds from Issuance of Common Stock	'	'	3,253,316	725,757
Proceeds from Issuance of Warrants	500,000	169,000	'	'
Round C Common Stock [Member]	'	'	'	'
Additional Paid In Capital Common Stock And Warrants, Share	375,399	'	'	'
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights adjustment Shares	10,704	'	'	'
Proceeds from Issuance of Common Stock	$1,500,000	$803,000	'	'

Subsequent_Events_Details_Text

Subsequent Events (Details Textual) (USD $)	3 Months Ended			1 Months Ended		2 Months Ended
	Mar. 31, 2013	Mar. 31, 2014	Dec. 31, 2013	Apr. 24, 2014	13-May-14	31-May-14	Apr. 30, 2014
				Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]
							Chief Executive Officer [Member]
Subsequent Event [Line Items]	'	'	'	'	'	'	'
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	'	'	'	'	'	0	'
Additional Paid In Capital Common Stock And Warrants	'	$2,000,000	'	'	$151,000	'	'
Additional Paid In Capital Common Stock And Warrants, Share	176,697	'	'	'	250	0	'
Common Stock Adjustment Shares	53,008	'	'	'	773	'	'
Due from Related Parties	'	'	'	'	'	'	28,500
Purchases Of Common Unit	'	'	'	3,636,364	'	'	'
Common Stock Exercise Price	'	'	'	$6.05	'	'	'
Class of Warrant or Right, Exercise Price of Warrants or Rights	'	'	'	5.5	'	'	'
Common stock, $0.0001 par value; 200,000,000 shares authorized; 32,015,480 and 31,568,629 shares issued and outstanding at March 31, 2014 and December 31, 2013, respectively.	'	3,202	3,157	20,000,000	'	'	'
Stock Issued During Period, Shares, New Issues	'	'	'	10,909,091	27,500	'	'
Common Stock, No Par Value	'	'	'	$5.50	'	'	'
Additional Paid in Capital, Common Stock	'	'	'	$60,000,000	'	'	'
Warrant To Purchase Common Stock	'	'	'	'	250	'	'